<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002217" GROUP_ID="EPILEPSY" ID="463400031309383521" MERGED_FROM="" MODIFIED="2012-11-29 15:31:39 +0000" MODIFIED_BY="Rachael Kelly" REVIEW_NO="0040" REVMAN_SUB_VERSION="5.2.1 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2012-11-29 15:31:39 +0000" MODIFIED_BY="Rachael Kelly">
<TITLE MODIFIED="2012-06-14 15:20:28 +0100" MODIFIED_BY="[Empty name]">Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures</TITLE>
<CONTACT MODIFIED="2012-11-29 15:31:39 +0000" MODIFIED_BY="Rachael Kelly"><PERSON ID="69987482149416066805111004173943" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Sarah</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Nolan</LAST_NAME><EMAIL_1>sarah.nolan@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Biostatistics</DEPARTMENT><ORGANISATION>University of Liverpool</ORGANISATION><ADDRESS_1>Shelley's Cottage</ADDRESS_1><ADDRESS_2>Brownlow Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L69 3GS</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-11-29 15:31:39 +0000" MODIFIED_BY="Rachael Kelly"><PERSON ID="69987482149416066805111004173943" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Sarah</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Nolan</LAST_NAME><EMAIL_1>sarah.nolan@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Biostatistics</DEPARTMENT><ORGANISATION>University of Liverpool</ORGANISATION><ADDRESS_1>Shelley's Cottage</ADDRESS_1><ADDRESS_2>Brownlow Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L69 3GS</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="13572" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Catrin</FIRST_NAME><LAST_NAME>Tudur Smith</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>cat1@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Biostatistics</DEPARTMENT><ORGANISATION>University of Liverpool</ORGANISATION><ADDRESS_1>Shelley's Cottage</ADDRESS_1><ADDRESS_2>Brownlow Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L69 3GS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 794 4059</PHONE_1><FAX_1>+44 151 794 4754</FAX_1></ADDRESS></PERSON><PERSON ID="12654466126280759364110830105954" ROLE="AUTHOR"><FIRST_NAME>Jennifer</FIRST_NAME><LAST_NAME>Pulman</LAST_NAME><EMAIL_1>jennifer.pulman@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="555BA85182E26AA20187B7968786091D" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Marson</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>a.g.marson@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 529 5405</PHONE_1><PHONE_2>+44 151 529 5462</PHONE_2><FAX_1>+44 151 529 5465</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-11-29 14:58:38 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="29" MONTH="11" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-29 14:58:19 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-11-01 10:29:54 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Updated May 2012</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-11-29 14:58:19 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Searches updated 31 May 2012; no new trials identified. 'Risk of bias' and 'Summary of findings' tables added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-06-21 09:39:52 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-06-21 09:39:52 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Searches updated 20 October 2009; no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-11-11 10:36:44 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="12" YEAR="2006"/>
<DESCRIPTION>
<P>Searches updated 22 December 2006; no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-06-18 18:50:49 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Liverpool</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal Liverpool and Broadgreen Hospital Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-06-18 18:50:49 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-06-18 18:50:49 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute of Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This review presents independent research commissioned by the National Institute for Health Research (NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-11-20 13:26:30 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-06-18 17:41:17 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-06-14 15:22:34 +0100" MODIFIED_BY="[Empty name]">Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures</TITLE>
<SUMMARY_BODY MODIFIED="2012-06-18 17:41:17 +0100" MODIFIED_BY="[Empty name]">
<P>Epilepsy is a disorder where recurrent seizures are caused by abnormal electrical discharges from the brain. Worldwide, phenobarbitone and phenytoin are commonly used antiepileptic drugs. This review found no evidence to suggest a difference between phenobarbitone and phenytoin for the control of the seizure types investigated. Phenobarbitone was more likely to be withdrawn than phenytoin, presumably due to adverse effects, however other factors may have influenced the rate of withdrawal of phenobarbitone in this review.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-11-20 12:23:46 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-11-20 12:23:19 +0000" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original Cochrane review published in <I>The Cochrane Library </I> 2001, Issue 4.</P>
<P>Worldwide, particularly in the developing world, phenytoin and phenobarbitone are commonly used antiepileptic drugs, primarily because they are inexpensive. The aim of this review is to summarise data from existing trials comparing phenytoin and phenobarbitone.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-06-18 18:52:06 +0100" MODIFIED_BY="[Empty name]">
<P>To review the best evidence comparing phenobarbitone and phenytoin when used as monotherapy in participants with partial onset seizures or generalised tonic-clonic seizures with or without other generalised seizure types.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-06-21 17:31:34 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Epilepsy Group trials register (31 May 2012), the Cochrane Central Register of Controlled Trials (CENTRAL Issue 5 of 12, <I>The Cochrane Library</I> 2012) and MEDLINE (1946 to May week 4, 2012). We hand-searched relevant journals, contacted pharmaceutical companies, original trial investigators and experts in the field.  </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-06-14 15:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials in children or adults with partial onset seizures or generalised onset tonic-clonic seizures with a comparison of phenobarbitone monotherapy with phenytoin monotherapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-11-20 12:23:43 +0000" MODIFIED_BY="[Empty name]">
<P>This was an individual participant data (IPD) review. Outcomes were time to (a) treatment withdrawal (b) 12-month remission (c) six-month remission and (d) first seizure post randomisation. Cox proportional hazards regression models were used to obtain study-specific estimates of hazard ratios (HRs) with 95% confidence intervals (CIs) with the generic inverse variance method used to obtain the overall pooled estimate of HRs and 95% CIs.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-11-20 12:23:46 +0000" MODIFIED_BY="[Empty name]">
<P>Data have been obtained for four of eight studies meeting the inclusion criteria, amounting to 599 individuals, or approximately 63% of the potential data.</P>
<P>The main overall results (pooled HR, 95% CI) were (a) time to treatment withdrawal 1.62 (1.23 to 2.14); (b) time to 12-month remission 0.90 (0.69 to 1.18) (c) time to six-month remission 0.92 (0.73 to 1.16) and (d) time to first seizure 0.85 (0.68 to 1.05). These results indicate a statistically significant clinical advantage for phenytoin in terms of treatment withdrawal. However, this result may have been confounded by several factors including substantial statistical heterogeneity between studies and lack of blinding in two studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-06-14 10:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>The results of this review show that phenobarbitone was significantly more likely to be withdrawn than phenytoin. Given that no significant differences for seizure outcomes were found, the higher withdrawal rate with phenobarbitone may be due to adverse effects. Several factors may have confounded the results of this review.  </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-11-20 13:26:30 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-11-20 12:23:51 +0000" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in The Cochrane Database of Systematic Reviews (2001, Issue 4) on 'Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures'.</P>
<P>Worldwide, phenytoin and phenobarbitone are commonly used antiepileptic drugs (AEDs). They are more likely to be used in the developing world than the developed world, primarily because they are inexpensive but in the USA and much of Europe, phenytoin and phenobarbitone are no longer considered first-line agents due to worries over adverse effects. Phenobarbitone is commonly associated with somnolence (sedation), with connective tissue abnormalities such as Dupuytrens contracture, and frozen shoulder (<LINK REF="REF-Baulac-2002" TYPE="REFERENCE">Baulac 2002</LINK>), whilst phenytoin is associated with coarsening of facial features and gum hypertrophy (<LINK REF="REF-Scheinfeld-2003" TYPE="REFERENCE">Scheinfeld 2003</LINK>). In addition, both drugs are teratogenic and are associated with low folic acid levels and megaloblastic anaemia.(<LINK REF="REF-Meador-2008" TYPE="REFERENCE">Meador 2008</LINK>), particularly phenytoin which is associated with fetal hydantoin syndrome (<LINK REF="REF-Scheinfeld-2003" TYPE="REFERENCE">Scheinfeld 2003</LINK>). Furthermore, due to the pharmacokinetic profile of phenytoin, the plasma concentrations are difficult to predict and dosing will usually need to be informed by measuring plasma concentration.</P>
<P>In the largest reported randomised controlled trial investigating phenobarbitone as monotherapy in adults (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>), no difference was found with respect to seizure control when compared with phenytoin and carbamazepine. However, for the outcome time to treatment withdrawal, phenobarbitone fared significantly worse, implying that it was less well tolerated. In children, there is concern about behavioural disturbances caused by phenobarbitone (<LINK REF="REF-Trimble-1988" TYPE="REFERENCE">Trimble 1988</LINK>). In one paediatric study in the UK (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>), the phenobarbitone arm of the trial was withdrawn due to concerns about adverse effects. However, another study based in rural India (<LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>) comparing phenobarbitone with phenytoin found no such problem, and the authors concluded that phenobarbitone was a suitable first-line agent in this setting.</P>
<P>Phenytoin and phenobarbitone are thought to be effective for both partial and generalised seizure types. No single trial has found convincing differences between phenytoin and phenobarbitone with respect to seizure control. However, confidence intervals around estimates have been wide and equivalence cannot be inferred. The aim of this review is to summarise data from existing trials comparing phenobarbitone and phenytoin.</P>
<P>There are difficulties in undertaking a systematic review of epilepsy monotherapy trials as the important efficacy outcomes require analysis of time-to-event data (for example, time to first seizure after randomisation). Although methods have been developed to synthesize time-to-event data using summary information (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>; <LINK REF="REF-Williamson-2002" TYPE="REFERENCE">Williamson 2002</LINK>), the appropriate statistics are not commonly reported in published epilepsy trials.</P>
<P>Furthermore, although seizure data have been collected in most epilepsy monotherapy trials, there has been no uniformity in the definition and reporting of outcomes. For example, trials may report time to 12-month remission but not time to first seizure or vice versa or some trials may define time to first seizure from the date of randomisation but others use date of achieving maintenance dose. Trial investigators have also adopted differing approaches to the analysis, particularly with respect to the censoring of time-to-event data. For these reasons, we performed this review using individual participant data (IPD) which helps to overcome these problems. This review is one in a series of IPD reviews investigating pairwise monotherapy comparisons.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-11-20 12:23:52 +0000" MODIFIED_BY="[Empty name]">
<P>To review the time to withdrawal, remission and first seizure of phenobarbitone compared with phenytoin when used as monotherapy in participants with partial onset seizures or generalised tonic-clonic seizures, with or without other generalised seizure types.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-11-20 12:24:50 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-11-20 12:23:58 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-11-20 12:23:54 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI> Randomised controlled trials using either:</LI>
<OL>
<LI>an adequate method of allocation concealment (e.g. sealed opaque envelopes);</LI>
<LI>a quasi method of randomisation (e.g. allocation by date of birth).</LI>
</OL>
<LI>Studies may be double blind, single blind or unblinded.</LI>
</OL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-11-20 12:23:54 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Children or adults with partial onset seizures (simple partial, complex partial or secondary generalised tonic-clonic), or generalised tonic-clonic seizures (with or without other generalised seizure types).</LI>
<LI>Individuals with a new diagnosis of epilepsy, or who have had a relapse following antiepileptic monotherapy withdrawal.</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-05-25 13:39:45 +0100" MODIFIED_BY="[Empty name]">
<P>Phenobarbitone (PB) or phenytoin (PHT) as monotherapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-11-20 12:23:58 +0000" MODIFIED_BY="[Empty name]">
<P>Below is a list of outcomes we investigated in this review. Reporting of these outcomes in the original trial report was not an eligibility requirement for inclusion in this review.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-06-18 18:53:03 +0100" MODIFIED_BY="[Empty name]">
<P>Time to withdrawal of allocated treatment (retention time). This is a combined outcome reflecting both efficacy and tolerability as treatment may be withdrawn due to continued seizures, adverse effects or a combination of both. This is an outcome to which the participant makes a contribution, and is the primary outcome measure recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy (<LINK REF="REF-ILAE-2006" TYPE="REFERENCE">ILAE 2006</LINK>).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-11-20 12:23:58 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to achieve a 12-month seizure-free period (remission).</LI>
<LI>Time to achieve a six-month seizure-free period (remission).</LI>
<LI>Time to first seizure post randomisation.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-09-17 14:29:29 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-09-17 14:29:29 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases. There were no language restrictions.</P>
<OL>
<LI>The Cochrane Epilepsy Group trials register (31 May 2012) using the search terms 'phenobarbital or phenobarbitone' and 'phenytoin'.</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL Issue 5 of 12, <I>The Cochrane Library </I>2012) using the strategy outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</LI>
<LI>MEDLINE (Ovid) (1946 to May week 4, 2012) was searched using the strategy outlined in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-17 16:04:06 +0100" MODIFIED_BY="[Empty name]">
<P>In addition, we handsearched relevant journals, and contacted pharmaceutical companies and researchers in the field to seek any ongoing or unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-11-20 12:24:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-11-20 12:23:59 +0000" MODIFIED_BY="[Empty name]">
<P>Trials were independently assessed for inclusion by two review authors (SJN and AGM). Any disagreements were resolved my mutual discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-11-20 12:24:05 +0000" MODIFIED_BY="[Empty name]">
<P>The following individual participant data were requested for all trials meeting our inclusion criteria.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Trial methods:</HEADING>
<P>(a) method of generation of random list;<BR/>(b) method of concealment of randomisation;<BR/>(c) stratification factors;<BR/>(d) blinding methods.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Participant covariates:</HEADING>
<P>(a) sex;<BR/>(b) age;<BR/>(c) seizure types;<BR/>(d) time between first seizure and randomisation;<BR/>(e) number of seizures prior to randomisation (with dates);<BR/>(f) presence of neurological signs (neurological deficits, learning difficulties etc);<BR/>(g) EEG (electroencephalography) results;<BR/>(h) computed tomography (CT)/magnetic resonance imaging (MRI) results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Follow-up data:</HEADING>
<P>(a) treatment allocation;<BR/>(b) date of randomisation;<BR/>(c) dates of follow-up;<BR/>(d) dates of seizures post randomisation or seizure frequency data between follow-up visits;<BR/>(e) dates of treatment withdrawal and reasons for treatment withdrawal;<BR/>(f) dose;<BR/>(g) dates of dose changes.</P>
<P>For each trial for which individual participant data were not obtained, an assessment was carried out to see whether any relevant aggregate level data had been reported.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-11-20 12:24:07 +0000" MODIFIED_BY="[Empty name]">
<P>All included studies were independently assessed for risk of bias by two review authors (SJN and JP).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-10-10 15:39:05 +0100" MODIFIED_BY="[Empty name]">
<P>All outcomes in this review were measured as time-to-event outcomes. Outcomes were calculated from IPD provided where possible or extracted from published studies.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-11-20 12:24:14 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>In two studies (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>), summary seizure data at each follow-up were provided, rather than specific dates of seizures. To allow combination with data from the other trials, we used linear interpolation to obtain estimates of the dates of seizures between follow-up visits. For example, if four seizures were recorded between two visits which occurred on 01/03/90 and 01/05/90 (an interval of 61 days), then the date of first seizure would be approximately 13/03/90. This allowed an estimate of the time of the six-month remission, time to 12-month remission and the time to first seizure to be computed.</LI>
<LI>Time to six- and 12-month remissions were calculated from the date of randomisation to the date (or estimated date) the individual had first been free from seizures for six or 12 months respectively.</LI>
<LI>Time to first seizure was calculated from the date of randomisation to the date that the first seizure was estimated to have occurred.</LI>
<LI>If seizure data were missing for a particular visit, these outcomes were censored at the previous visit. These outcomes were also censored if the individual died or follow-up ceased prior to the event of interest.</LI>
<LI>For the analysis of time to withdrawal of allocated treatment, an event was defined to be the withdrawal of the allocated treatment due to poor seizure control or side effects or both. Non-compliance with the treatment regimen or the addition of another anti-epileptic drug were also classed as events. The outcome was censored if the treatment was withdrawn because the individual achieved a period of remission or if the individual was still on the allocated treatment at the end of follow-up.</LI>
</UL>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-11-20 12:24:17 +0000" MODIFIED_BY="[Empty name]">
<P>For each trial where IPD were supplied in the original review, results were reproduced from trial results where possible and the following consistency checks were performed.</P>
<P>(a) Trial details were cross checked against any published report of the trial and original trial authors were contacted if missing data, errors or inconsistencies were found.<BR/>(b) Review of the chronological randomisation sequence. The balance of prognostic factors were checked, taking account of factors stratified for in randomisation procedure.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-06-14 14:41:20 +0100" MODIFIED_BY="[Empty name]">
<P>Stratified logrank tests (stratified by trial to preserve the within trial randomisation) were used to test statistical significance of treatment effect sizes and to assess evidence of heterogeneity in drug effect between trials (<LINK REF="REF-EBCTCG-1990" TYPE="REFERENCE">EBCTCG 1990</LINK>). </P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-11-20 12:24:20 +0000" MODIFIED_BY="[Empty name]">
<P>A full quality and 'Risk of bias' assessment was undertaken independently by two review authors (SJN and JP). Any selective reporting bias detected could be assessed with the ORBIT classification system (<LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-11-20 12:24:28 +0000" MODIFIED_BY="[Empty name]">
<P>We carried out our analysis on an intention-to-treat basis (that is, participants were analysed in the group to which they were randomised, irrespective of which treatment they actually received). Therefore for time-to-event outcomes 'time to six-month remission', 'time to 12-month remission' and 'time to first seizure post randomisation' participants were not censored if treatment was withdrawn.</P>
<P>For all outcomes, the relationship between the time-to-event and treatment effect of the anti-epileptic drugs was investigated. Cox proportional hazards regression models were used to obtain study-specific estimates of log (hazard ratio) or treatment effect and associated standard errors in the statistical software SAS version 9.2. (Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.). The model assumes that the ratio of hazards (risks) between the two treatment groups is constant over time (i.e. hazards are proportional). This proportional hazards assumption of the Cox regression model was tested for each outcome of each study by testing the statistical significance of a time-varying covariate in the model. Overall estimates of hazard ratios (with 95% confidence intervals) were evaluated via the generic inverse-variance method in Metaview.</P>
<P>Results are expressed as a hazard ratio (HR) and 95% confidence interval, and by convention an HR &gt; 1 indicates that an event is more likely to occur earlier on phenobarbitone than phenytoin. Hence, for time to withdrawal of allocated treatment or time to first seizure an HR &gt; 1 indicates a clinical advantage for phenytoin (e.g. HR = 1.2 would suggest a 20% increase in risk of withdrawal from phenobarbitone compared with phenytoin) and for time to six- and 12-month remissions an HR &gt; 1 indicates a clinical advantage for phenobarbitone.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-11-20 12:24:33 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the potential impact of seizure type on results, all analyses were stratified by seizure type (partial onset versus generalised onset), according to the classification of main seizure type recorded at baseline. Partial seizures (simple or complex) and partial secondarily generalised seizures were classified as partial epilepsy. Primarily, generalised seizures were classified as generalised epilepsy. We conducted a Chi<SUP>2</SUP> test of interaction between treatment and seizure type.</P>
<P>If significant statistical heterogeneity was found to be present, meta-analysis was performed with a random-effects model in addition to a fixed-effect model and the results of both models were presented and we performed sensitivity analyses to investigate differences in study characteristics.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-11-20 12:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>Due to serious drug-related side effects, the phenobarbitone arm was discontinued in one trial (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>) after randomising only 10 children to this drug. Following the removal of the phenobarbitone arm, further randomisation continued between phenytoin, carbamazepine and sodium valproate (the remaining drugs examined in the trial). In order to assess whether this had any effect on the comparison between phenobarbitone and phenytoin, sensitivity analyses were undertaken for each outcome; (i) excluding individuals who were randomised to phenytoin after the removal of phenobarbitone in <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> and (ii) excluding study <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> from the analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-11-20 13:26:30 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-11-20 12:25:00 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-11-20 12:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>Eight studies were identified as eligible for this systematic review.</P>
<P>For the most recent update of this review (June 2012), the search of MEDLINE retrieved 10 hits, and the search of CENTRAL retrieved four hits. The search of the Cochrane Epilepsy Group's Specialised Register returned no new hits. After duplicate reports and clearly irrelevant reports were removed, one study (<LINK REF="STD-Verma-2010" TYPE="STUDY">Verma 2010</LINK>) was assessed for eligibility and subsequently excluded from the review (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-11-20 12:24:58 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;b&gt;Referee comment:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;I would have liked to know more background about the study Pal1998 in rural India, since these medications are often used in the developing world. Also, the results of the research raised several questions of its trustworthiness etc. I do understand that you did bias investigation, but nevertheless &amp;#8230; Where facts omitted from the participants, how informed were they, how much was reported back and external influence&amp;#8230;My apologies for a suspicious mind&lt;/p&gt;&lt;p&gt;&lt;b&gt;Authors' response:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-10-04 14:10:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;I agree it is interesting to have studies from both the developed and developing world in th&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:11:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;e same meta-analysis&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:18:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;. I hav&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:19:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;e added some text to the included studies and discussion section to emphasise the potential importance of the country the study is based in&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:35:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; as this may change the perspective and aims of the study&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:19:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-10-04 14:19:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;In terms of any problems with trust&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:20:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;worthiness regarding Pal 1998, myself and another reviewer have both conducted risk of bias and noted any issues from the published paper. The authors of the paper state that verbal&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:21:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; consent was made with the parents of children in the study and that the study was given ethical approval.&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:22:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; Regu&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:35:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;la&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:22:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;r clinic visits and the involvement of fieldworkers suggests patients and families were regularly visited &lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:23:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;and from my view, the paper suggests no evidence of external influence. Everything suggests that the study was properly designed and patients / parents were properly informed.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-10-04 14:35:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;When the IPD &lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:36:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;was obtained for Pal 1998 in the original review&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:37:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;, all consistency checks were performed before the data was included in the review. From the re-analysis of the data, the results don't appear to be substantially different from those of the other studies which provided IPD (r&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:38:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;esults for 12 month remission are a bit extreme as the length of the study was 12 months so only a few children actually achieved 12 month remission) so I have no evidence to question the trustworthiness of Pal 1998.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-10-04 14:39:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;If any anecdotal reasons exist for questioning Pal 1998, I am not aware of them. Also, I'm not sure how or w&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:40:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;hether it would be appropriate to bring anecdotal evidence into a meta-analysis&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:41:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;. I hope you can understand my point of view.&lt;/span&gt;&lt;span modified=&quot;2012-10-04 14:23:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-10-04 14:27:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-10-04 14:23:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-11-20 12:24:58 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>Five of the studies recruited adults (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>; <LINK REF="STD-Czapinski-1997" TYPE="STUDY">Czapinski 1997</LINK>; <LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>) and three recruited children (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>; <LINK REF="STD-Thilothammal-1996" TYPE="STUDY">Thilothammal 1996</LINK>). Four studies recruited individuals with partial onset and generalised onset seizures (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>; <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>), two recruited individuals with partial onset seizures only (<LINK REF="STD-Czapinski-1997" TYPE="STUDY">Czapinski 1997</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>), one recruited individuals with generalised onset seizures only (<LINK REF="STD-Thilothammal-1996" TYPE="STUDY">Thilothammal 1996</LINK>) and one study gave insufficient information on seizure types (<LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>). Three studies were conducted in Europe (<LINK REF="STD-Czapinski-1997" TYPE="STUDY">Czapinski 1997</LINK>; <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>), three studies were conducted in the USA (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>; <LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>) and two studies were conducted in India (<LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>; <LINK REF="STD-Thilothammal-1996" TYPE="STUDY">Thilothammal 1996</LINK>).</P>
<P>Individual participant data (IPD) was obtained for four of the eight studies (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>), amounting to 599 participants which is 63% of the potential data. However, IPD for 'time to treatment withdrawal' was not provided for one of these four studies (<LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>). In these studies, data were available for the following individual participant factors: type of epilepsy (100%); sex (99.5%); age at randomisation (99.5%); time between first seizure and randomisation (99%) and number of seizures pre-randomisation (92.2%). EEG and CT data were computerised for one of the studies (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>), but have not been computerised for the other three studies providing IPD. Similar problems occurred in the assessment of neurological signs. The largest study (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>) contributing 320 participants (53%) of the IPD recruited participants with partial onset seizures only, therefore, of the 599 participants analysed, only 131 (22%) had generalised onset seizures.</P>
<P>No IPD could be obtained for the remaining four studies (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>; <LINK REF="STD-Czapinski-1997" TYPE="STUDY">Czapinski 1997</LINK>; <LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>; <LINK REF="STD-Thilothammal-1996" TYPE="STUDY">Thilothammal 1996</LINK>), none of which reported sufficient aggregate level data to contribute to the outcomes chosen for this review. Two studies (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>; <LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>) used cross-over designs with differing lengths of drug treatment period, ranging from one to three weeks. These treatment periods are relatively short in terms of the outcome measures chosen for this review.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-11-20 12:25:00 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details and reasons for exclusions from this review.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-11-20 13:26:30 +0000" MODIFIED_BY="[Empty name]">
<P>For further details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="3">(1) Trials for which individual participant data were provided</HEADING>
<P>Two of the trials used randomised participants via a random list generated from random permuted blocks and used sealed opaque envelopes as the method of concealment of randomisation (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>). One trial randomised participants with a prepared random number list and by minimisation (<LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>) and one trial did not state the method of randomisation or allocation concealment used (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>)</P>
<P>Two trials were unblinded for "practical and ethical reasons" (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>), one trial was double blinded (participants and personnel) achieved using an additional placebo tablet (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>) and one trial was single blinded with outcome assessors blinded only (<LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Trials for which no individual participant data were available</HEADING>
<P>One trial randomised participants via random number tables (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>) and one trial using computer-generated random numbers (<LINK REF="STD-Thilothammal-1996" TYPE="STUDY">Thilothammal 1996</LINK>). The method of allocation concealment was not stated in any of the four studies. Three of the trials were double blinded (participants and personnel), achieved using additional blank tablets (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>;<LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>; <LINK REF="STD-Thilothammal-1996" TYPE="STUDY">Thilothammal 1996</LINK>). Blinding was not mentioned in <LINK REF="STD-Czapinski-1997" TYPE="STUDY">Czapinski 1997</LINK>.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-11-20 12:26:07 +0000" MODIFIED_BY="[Empty name]">
<P>A summary of the outcomes reported in studies for which no individual participant data (IPD) were available is given in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Details regarding the number of individuals (with IPD) contributing to each analysis are given in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. All results are summarised in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> and Meta View. Survival curve plots are shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>; <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>; <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>; <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>. All survival curve plots were produced in Stata software version 11.2 (<LINK REF="REF-Stata-2009" TYPE="REFERENCE">Stata 2009</LINK>) using data from all trials providing IPD combined.</P>
<SUBSECTION>
<HEADING LEVEL="3">(1) Time to withdrawal of allocated treatment</HEADING>
<P>For this outcome, a hazard ratio (HR) &gt; 1 indicates a clinical advantage for phenytoin</P>
<P>Time to withdrawal of allocated treatment was available for 499 individuals in three trials supplying IPD (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>). Withdrawal information was not available for <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>.</P>
<P>The overall pooled HR is 1.62 (95% confidence interval (CI) 1.23 to 2.14, P = 0.0006), calculated with fixed effects indicating that phenobarbitone was significantly more likely to be withdrawn than phenytoin. However, there was evidence of statistical heterogeneity between the trials (Chi<SUP>2</SUP> = 6.68, df = 2, P = 0.04, I<SUP>2</SUP>= 70%). To account for this heterogeneity the HR is also calculated with random effects; the HR was 2.11 (95% CI 1.10 to 4.03. P = 0.02, Tau<SUP>2</SUP> = 0.23) indicating that when variation between trials is accounted for, phenobarbitone was still significantly more likely to be withdrawn than phenytoin. The proportional hazards assumption of the Cox model was satisfied for all study specific estimates of the log (hazard ratio). A possible source of heterogeneity is combining two studies of adults (<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>) with a study of children only (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>); when <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK> and <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK> only are pooled, overall, the HR is 1.47 (95% CI 1.10 to 1.96, P = 0.009) and statistical heterogeneity between trials is reduced (Chi<SUP>2</SUP> = 2.21, df = 1, P = 0.14, I<SUP>2 </SUP>= 55%).</P>
<P>For participants with generalised seizures (n = 95), the pooled HR (calculated with fixed effects) is 4.04 (95% CI 1.61 to 10.14, P = 0.003) indicating a statistically significant advantage for phenytoin. For participants with partial onset seizures (404), the pooled HR (fixed effects) was 1.48 (95% CI 1.10 to 1.98, P = 0.009), again indicating a statistically significant advantage for phenytoin. Overall, the pooled HR (adjusted for seizure type, fixed effects) is 1.62 (95% CI 1.23 to 2.14, P = 0.0007) indicating an overall statistically significant advantage for phenytoin; that phenobarbitone was significantly more likely to be withdrawn than phenytoin. A test for interaction between treatment effect and epilepsy type (partial onset versus generalised onset) was statistically significant (Chi<SUP>2</SUP> = 4.18, df = 1, P = 0.04)</P>
<P>However, substantial heterogeneity was present between the trials, within the subgroup of participants with partial onset seizures (Chi<SUP>2</SUP> = 4.15, df = 2, P = 0.13, I<SUP>2 </SUP>= 52%). To account for this heterogeneity the hazard ratios are also calculated with random effects; for participants with generalised seizures (95), the pooled HR is unchanged as no heterogeneity is present. For participants with partial onset seizures (404), the pooled HR was 1.84 (95% CI 0.98 to 3.45, P = 0.06) suggesting an advantage for phenytoin but this advantage is no longer statistically significant. Overall, the pooled HR (adjusted for seizure type) for the random-effects analysis is 2.32 (95% CI 1.29 to 4.17, P = 0.005) indicating that phenobarbitone was significantly more likely to be withdrawn than phenytoin. When heterogeneity is accounted for with random effects, the test for interaction between treatment effect and epilepsy type is no longer statistically significant (Chi<SUP>2</SUP> = 1.92, df = 1, P = 0.17).</P>
<P>Sensitivity analysis was conducted excluding those in <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> randomised to phenytoin after phenobarbitone was discontinued due to adverse events (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). For participants with generalised seizures (74), the pooled HR was 4.01 (95% CI 1.29 to 12.41. P = 0.02) indicating a statistically significant advantage for phenytoin. For participants with partial onset seizures (379), the pooled HR was 1.54 (95% CI 1.03 to 2.30, P = 0.04), again indicating a statistically significant advantage for phenytoin. Overall, the pooled HR (adjusted for seizure type) is 1.89 (95% CI 1.15 to 3.09, P = 0.01) indicating that phenobarbitone was significantly more likely to be withdrawn than phenytoin.</P>
<P>A second sensitivity analysis was conducted excluding <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> from the meta-analysis (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). For participants with generalised seizures (67), the pooled HR was 4.42 (95% CI 1.23 to 15.87. P = 0.02) indicating a statistically significant advantage for phenytoin. For participants with partial onset seizures (379), the pooled HR was 1.38 (95% CI 1.02 to 1.86, P = 0.04) again indicating a statistically significant advantage for phenytoin Overall, the pooled HR (adjusted for seizure type) is 1.47 (95% CI 1.09 to 1.96, P = 0.01) indicating that phenobarbitone was significantly more likely to be withdrawn than phenytoin. When these exclusions are made, heterogeneity is substantially reduced for participants with partial onset seizures, the I<SUP>2</SUP> is reduced from 52% to 0%. There is some indication of an association between treatment effect and seizure type in the sensitivity analysis, however, the test for interaction is not statistically significant (Chi<SUP>2</SUP> = 3.03, df = 1, P = 0.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Time to 12-month remission</HEADING>
<P>For this outcome, an HR &gt; 1 indicates a clinical advantage for phenobarbitone</P>
<P>Time to withdrawal of allocated treatment was available for 599 individuals in four trials supplying IPD (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>;<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>). The length of follow-up in <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK> was 12 months and only 19 of the original 94 participants in the trial completed 12 months of follow-up and of these 19 participants, only eight (one generalised seizures, seven partial seizures) achieved 12-month remission. Therefore, stratified HR estimates for <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK> are based on small numbers.</P>
<P>The overall pooled HR was 0.90 (95% CI 0.69 to 1.18, P = 0.44), indicating an advantage for phenytoin which is not statistically significant. There was no evidence of statistical heterogeneity between the trials (Chi<SUP>2</SUP> = 1.17, df = 3, P = 0.76, I<SUP>2 </SUP>= 0%). The proportional hazards assumption of the Cox model was satisfied for all study specific estimates of the log (hazard ratio). </P>
<P>For participants with generalised seizures (131), the pooled HR was 0.77 (95% CI 0.46 to 1.28, P = 0.31) indicating an advantage for phenytoin which is not statistically significant. For participants with partial onset seizures (468), the pooled HR was 0.96 (95% CI 0.70 to 1.33, P = 0.82) indicating no clear advantage for either drug. Overall, the pooled HR (adjusted for seizure type) is 0.90 (95% CI 0.69 to 1.19, P = 0.46) indicating an advantage for phenytoin but is not statistically significant. No interaction between treatment effect and epilepsy type (partial onset versus generalised onset) was found (chi squared = 0.53, df = 1, P = 0.47)</P>
<P>In sensitivity analysis (i) excluding those in <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> randomised to phenytoin after phenobarbitone was discontinued due to adverse events and (ii) excluding trial <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>), HR estimates were very similar and conclusions were unchanged.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(3) Time to six-month remission</HEADING>
<P>For this outcome, an HR &gt; 1 indicates a clinical advantage for phenobarbitone.</P>
<P>Time to withdrawal of allocated treatment was available for 599 individuals in four trials supplying IPD (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>;<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>).</P>
<P>The overall pooled HR was 0.92 (95% CI 0.73 to 1.16 , P = 0.47), indicating an advantage for phenytoin which is not statistically significant. There was no evidence of statistical heterogeneity between the trials (Chi<SUP>2</SUP> = 2.15, df = 3, P = 0.54, I<SUP>2 </SUP>= 0%).</P>
<P>For participants with generalised seizures (131), the pooled HR was 0.79 (95% CI 0.51 to 1.24 , P = 0.31) indicating an advantage for phenytoin which is not statistically significant. For participants with partial seizures (468), the pooled HR was 0.94 (95% CI 0.71 to 1.25, P = 0.69) indicating no clear advantage for either drug. Overall, the pooled HR (adjusted for seizure type) is 0.90 (95% CI 0.71 to 1.14, P = 0.38) indicating an advantage for phenytoin which is not statistically significant. No interaction between treatment effect and epilepsy type (partial onset versus generalised onset) was found (Chi<SUP>2</SUP> = 0.43, df = 1, P = 0.51)</P>
<P>In a sensitivity analysis (i) excluding those in <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> randomised to phenytoin after phenobarbitone was discontinued due to adverse events and (ii) excluding trial <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>), HR estimates were very similar and conclusions were unchanged.</P>
<P>In <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>, there is evidence that the proportional hazards assumption of the Cox regression model is violated (see <LINK TAG="DATA_SYNTHESIS" TYPE="SECTION">Data synthesis</LINK>); the P value of time varying covariate is 0.013 and from visual inspection of the survival plot (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>), the curves cross and hazards become non-proportional around 300 days. In other words, it is possible that the treatment effect is not constant throughout follow-up, and this change seems to happen at around 300 days. As <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK> provides over half of the data contributing to this outcome, sensitivity analysis was performed for all participants by analysing separately those who achieved six-month remission of seizures before and after 300 days.</P>
<P>Results of sensitivity analysis show that 79 (13%) out of 599 participants achieved six-month remission of seizures after 300 days (20 from <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>, 30 from <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>, 24 from <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK> and five from <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>). From sensitivity analysis (i) for those who achieved six-month remission before 300 days, the pooled HR was 1.13 (95% CI 0.86 to 1.48, P = 0.39) indicating an advantage for phenobarbitone which is not statistically significant and for those who achieved six-month remission after 300 days, the pooled HR was 0.61 (95% CI 0.37 to 1.00, P = 0.05) indicating a statistically significant advantage to phenytoin. There is evidence of a difference between subgroups of participants (test of interaction: Chi<SUP>2</SUP> = 4.61, df = 1, P = 0.03) indicating an possible association between phenobarbitone and 'early' remission" and phenytoin and 'later' remission, however, care is needed with interpretation as this association may be influenced by withdrawal rates due to side effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(4) Time to first seizure</HEADING>
<P>For this outcome, an HR &gt; 1 indicates a clinical advantage for phenytoin</P>
<P>Time to first seizure was available for 592 individuals in four trials supplying IPD (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>;<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>).</P>
<P>The overall pooled HR was 0.85 (95% CI 0.68 to 1.05, P = 0.14), indicating an advantage for phenobarbitone which is not statistically significant. There was no evidence of statistical heterogeneity between the trials (Chi<SUP>2</SUP> = 2.80, df = 3, P = 0.42). The proportional hazards assumption of the Cox model was satisfied for all study specific estimates of the log (hazard ratio).</P>
<P>For participants with generalised seizures (131), the pooled HR was 1.14 (95% CI 0.73 to 1.78, P = 0.56) indicating an advantage for phenytoin which is not statistically significant. For participants with partial onset seizures (461), the pooled HR was 0.78 (95% CI 0.61 to 1.01, P = 0.06) indicating a borderline statistically significant advantage for phenobarbitone. Overall, the pooled HR (adjusted for seizure type) is 0.86 (95% CI 0.69 to 1.08, P = 0.19) indicating an advantage for phenobarbitone which is not statistically significant. No interaction between treatment effect and epilepsy type (partial onset versus generalised onset) was found (Chi<SUP>2</SUP> = 2.04, df = 1, P = 0.15, I<SUP>2 </SUP>= 0%)</P>
<P>In a sensitivity analysis (i) excluding those in <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> randomised to phenytoin after phenobarbitone was discontinued due to adverse events and (ii) excluding trial <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>), HR estimates were very similar and conclusions were unchanged.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-11-20 12:26:26 +0000" MODIFIED_BY="[Empty name]">
<P>Eight trials met our inclusion criteria for this review, in that individuals with partial onset seizures or generalised onset tonic-clonic seizures were randomly allocated to monotherapy with either phenytoin or phenobarbitone. We were able to obtain individual participant data (IPD) for only four of these trials for at least three of the outcomes of interest, which represents 63% of the potentially available data. All four trials provided data for the outcome time to first seizure post randomisation (592 individuals), time to 12-month remission (599 individuals) and time to six-month remission (599 individuals), whilst three (499 individuals) provided data on time to treatment withdrawal. Individual participant withdrawal information was not provided for <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK> so this study could not contribute to the primary outcome.</P>
<P>The trials for which IPD were made available were of generally good quality, with <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK> and <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK> describing adequate methods of randomisation and <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>, <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK> and <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK> describing adequate methods of allocation concealment. However <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>, the largest study providing over half of the IPD, did not state how randomisation was carried out and this study recruited only participants with partial onset seizures leading to an imbalance between participants with partial onset (78%) and generalised seizures (22%) in the overall analysis. Due to this imbalance, pooled results for participants with generalised seizures are less precise and confidence intervals (CIs) are wider than the results for participants with partial seizures. Furthermore, it is not clear from <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK> how many participants were "untreated," how many were "undertreated" and how "undertreated" was defined in the study; i.e. can it be assumed that participants with no prior treatment and a small amount of prior treatment are clinically similar? A further difference between the four trials is that two recruited children only (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>) and two recruited adults only (<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>).</P>
<P>Of the four trials for which no IPD were made available, none reported the outcomes of interest in this review and as a result, we were unable to use aggregate data from trial reports in this review. Also, two of the four used cross-over designs with relatively short treatment periods and hence were not designed to examine the outcomes of interest in this review. Three of the four trials (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>; <LINK REF="STD-Czapinski-1997" TYPE="STUDY">Czapinski 1997</LINK>;<LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>) provided little or no information regarding generation of a random list and none of the four trials described a clear and an adequate method of allocation concealment, raising the issue of study quality. Furthermore, in the published information from two of the trials (<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>; <LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>), it is difficult to tell whether the participants involved had experienced new onset seizures or were receiving anti-epileptic drug treatment prior to trial recruitment. </P>
<P>For remission outcomes, we found no statistically significant difference between phenobarbitone and phenytoin for overall or subgroup analyses stratified by seizure type. There are consistent non-significant trends in overall and subgroup analyses favouring phenytoin for seizure remission (time to 12-month remission pooled HR (stratified by seizure type) 0.90 (95% CI 0.69 to 1.18) and time to six-month remission pooled hazard ratio (HR) (stratified by seizure type) 0.92 (95% CI 0.70 to 1.16)) but confidence intervals around summary estimates for HRs are relatively wide and do not suggest equivalence. Also, sensitivity analysis suggests possible association between phenobarbitone and 'early' remission and phenytoin and 'later' remission, however care is needed with interpretation as this association may be influenced by withdrawal rates due to side effects and not enough participants achieved 'late' remission to investigate this hypothesis further.</P>
<P>For time to first seizure, overall analyses show a non-significant advantage for phenobarbitone, pooled HR (stratified by seizure type) 0.86 (95% CI 0.69 to 1.08), a larger advantage for phenobarbitone for participants with partial onset seizures, pooled HR 0.78 (95% CI 0.61 to 1.01) and a non significant advantage for phenytoin for participants with generalised seizures, pooled HR 1.14 (95% CI 0.73 to 1.78). The confidence interval for participants with generalised onset seizures is much wider than for participants with partial onset seizures, showing the effect of the imbalance of seizure types in the pooled analysis.</P>
<P>For our primary outcome, we found that participants taking phenobarbitone were statistically significantly more likely to have treatment withdrawn, with an HR (stratified by seizure type) of 1.62 (95% CI 1.23 to 2.14). The fact that a clear advantage for phenytoin was not seen for the seizure outcomes reported would imply that treatment was withdrawn primarily because of adverse effects. There was however, significant heterogeneity for this outcome, which was not present for remission and seizure outcomes, therefore, obvious differences such as combining studies recruiting adults only and children only (such studies were combined for all outcomes) are unlikely to explain all of the heterogeneity observed for time to treatment withdrawal.<BR/>
</P>
<P>In three of the four trials (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>), participants and personnel were unblinded to treatment allocation (outcome assessors were blinded in <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>). The authors of the three unblinded trials state that blinding would not have been "practical" or "ethical" and would have resulted in a large withdrawal rate as blinding does not conform to standard clinical practice of increasing drug doses to therapeutic ranges (<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>). This effect is demonstrated by the unblinded study (<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>) with a 29% withdrawal rate (34 out of 116 participants withdrew from treatment, 40% from phenobarbitone and 20% from phenytoin) and the blinded study (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>) with a 48% withdrawal rate (152 out of 320 participants withdrew from treatment, 51% from phenobarbitone and 44% from phenytoin). The unblinded study (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>) had a withdrawal rate of 40% (25 out of 63 participants), however, this rate is influenced by the high withdrawal rate of phenobarbitone (eight out of 10 (80%) participants withdrew from phenobarbitone while 17 out of 53 (32%) withdrew from phenytoin). Therefore, the withdrawal rates of phenobarbitone compared with phenytoin are much higher, at least double, in the unblinded studies based in the UK (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>) while the withdrawal rates are more comparable in the double-blinded study conducted in the USA (<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>).</P>
<P>This suggests a potential explanation for the heterogeneity observed; clinicians, particularly clinicians in the UK, may have a prior opinion of particular anti-epileptic drugs and may expect adverse effects from phenobarbitone and would therefore be more likely to withdraw participants from this drug in an unblinded trial. Further, it is interesting to note that the UK trial recruiting children (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>) suspended randomisation to phenobarbitone due to serious adverse effects after 10 children had been randomised to that drug, whereas this problem was not reported in a trial recruiting children conducted in India (<LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>), in which phenobarbitone is concluded to be an "effective and acceptable antiepileptic drug for rural Indian children." These two studies may have been conducted from different perspectives due to the country of recruitment; <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> in the UK where concerns had been raised over the suitability of drugs such as phenobarbitone due to documented cases of adverse effects and <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK> in rural India where income is limited, newer generation antiepileptic drugs (AEDs) are not readily available or affordable and therefore, drugs such as phenobarbitone are more likely to be used.</P>
<P>Sensitivity analyses in this review show that heterogeneity of the time to withdrawal of allocated treatment outcome is reduced dramatically, particularly among participants with partial seizures, when <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> is excluded from analysis, therefore, it is likely that the perception of phenobarbitone as an antiepileptic treatment and lack of blinding in two out of three studies included in the analysis has influenced the results of the primary outcome of this review. Unfortunately, there are too few studies in this review to investigate these hypotheses further.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-11-20 12:26:26 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-06-06 10:38:18 +0100" MODIFIED_BY="[Empty name]">
<P>The results of this review do not provide evidence on which a choice can be made between phenytoin and phenobarbitone with respect to seizure control. Phenytoin is significantly less likely to be withdrawn however, presumably due to adverse effects, making it the preferred choice of the two drugs compared in this review. However, lack of masking in two studies may have influenced withdrawal rates of the two drugs, particularly phenobarbitone. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-20 12:26:26 +0000" MODIFIED_BY="[Empty name]">
<P>Finding overall differences between these two antiepileptic drugs has proved elusive. If overall differences do exist across heterogeneous populations of individuals such as those studied here, those differences are likely to be small, and in order to be clinically useful, future comparative antiepileptic drug studies will need to be powered accordingly. It has been argued that future comparative antiepileptic drug studies should be powered to establish equivalence (<LINK REF="REF-Jones-1996" TYPE="REFERENCE">Jones 1996</LINK>), and therefore be capable of detecting what is considered the smallest important clinical difference, however, it is unlikely that future studies will make a comparison between these two drugs as both drugs are no longer considered to be first-line agents.</P>
<P>The International League Against Epilepsy (<LINK REF="REF-ILAE-2006" TYPE="REFERENCE">ILAE 2006</LINK>) recommends time to treatment withdrawal (retention time) as the primary outcome in comparative monotherapy trials. One explanation for the heterogeneity observed for this outcome in this review is that clinicians were biased towards withdrawing phenobarbitone, leading to a higher withdrawal rate in unblinded studies. The issue of blinding will need to be considered in future pragmatic trials. Blinding significantly increases the cost of a trial and results in a departure from the everyday clinical practice that pragmatic trials try to mirror. However where there is prejudice against a particular treatment, failure to blind may result in a significant bias for this outcome.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-11-20 12:26:26 +0000" MODIFIED_BY="[Empty name]">
<P>We acknowledge Steven Taylor as lead investigator on the original review and Paula Williamson for contributions to the original review.</P>
<P>We are grateful to Cochrane Epilepsy Group Trial Search Co-ordinator Alison Beamond for performing all electronic searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-11-20 12:26:29 +0000" MODIFIED_BY="[Empty name]">
<P>SJ Nolan assessed studies for inclusion, assessed risk of bias in all included studies, performed analyses in SAS version 9.2 and Metaview, added survival plots and the 'Summary of findings' table and updated the text of the review under the supervision of C Tudur Smith and AG Marson.</P>
<P>AG Marson obtained individual participant data from original trial investigators and provided guidance with the clinical interpretation of results.</P>
<P>J Pulman independently assessed risk of bias in all included studies.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-11-20 13:28:33 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-06-21 17:14:44 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-11-29 11:16:41 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cereghino-1974" NAME="Cereghino 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG</AU>
<TI>Carbamazepine for epilepsy: a controlled prospective evaluation</TI>
<SO>Neurology</SO>
<YR>1974</YR>
<VL>24</VL>
<NO>5</NO>
<PG>401-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czapinski-1997" NAME="Czapinski 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czapinski P, Terczynski A, Czapinska E</AU>
<TI>Randomised 36-month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1997</YR>
<VL>150</VL>
<PG>162-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Silva-1996" NAME="de Silva 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Silva M, MacArdle B, McGowan M, Hughes E, Stewart K, Neville BG</AU>
<TI>Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>709-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruber-1962" NAME="Gruber 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruber CM, Brock JT</AU>
<TI>Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital and methylphenylhydantoin in motor seizures</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1962</YR>
<VL>3</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heller-1995" NAME="Heller 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL et al</AU>
<TI>Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1995</YR>
<VL>58</VL>
<NO>1</NO>
<PG>44-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattson-1985" NAME="Mattson 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR et al</AU>
<TI>Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures</TI>
<SO>New England Journal of Medicine</SO>
<YR>1985</YR>
<VL>313</VL>
<NO>3</NO>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pal-1998" NAME="Pal 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pal DK, Das T, Chaudhury G, Johnson AL, Neville BGR</AU>
<TI>Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thilothammal-1996" NAME="Thilothammal 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thilothammal N, Banu K, Ratnam RS</AU>
<TI>Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double-blind study</TI>
<SO>Indian Pediatrics</SO>
<YR>1996</YR>
<VL>33</VL>
<NO>7</NO>
<PG>549-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-06-21 17:14:44 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bird-1966" MODIFIED="2011-11-29 11:15:31 +0000" MODIFIED_BY="[Empty name]" NAME="Bird 1966" YEAR="1966">
<REFERENCE MODIFIED="2011-11-29 11:15:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bird CAK, Griffin BP, Miklaszewka JM, Galbraith AW</AU>
<TI>Tegretol (carbamazepine): a controlled trial of a new anti-convulsant</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1966</YR>
<VL>112</VL>
<PG>737-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cereghino-1975" NAME="Cereghino 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG</AU>
<TI>The efficacy of carbamazepine combinations in epilepsy</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1975</YR>
<VL>18</VL>
<NO>6</NO>
<PG>733-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meador-1990" MODIFIED="2011-11-29 11:16:41 +0000" MODIFIED_BY="[Empty name]" NAME="Meador 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-11-29 11:16:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meador K, Loring D, Huh K, Gallagher B, King D</AU>
<TI>Comparative cognitive effects of anticonvulsants</TI>
<SO>Neurology</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>3 Pt 1</NO>
<PG>391-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verma-2010" MODIFIED="2012-06-21 17:14:44 +0100" MODIFIED_BY="[Empty name]" NAME="Verma 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-21 17:14:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Verma G, Pathak U, Jaiswal V, Upadhyay A</AU>
<TI>Comparision of phenobarbitone with phenytoin for the treatment of seizures in term and near term neonates</TI>
<SO>Pediatric Academic Societies Annual Meeting, 1-4 May 2010, Vancouver. Abstract No: 2849.304. http://www.abstracts2view.com/pasall/view.php?nu=PAS10L1_1706</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1966" NAME="White 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White TW, Plott D, Norton J</AU>
<TI>Relative anticonvulsant potency of primidone</TI>
<SO>Archives of Neurology</SO>
<YR>1966</YR>
<VL>14</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-11-24 16:02:29 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-11-20 13:28:33 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-11-20 13:28:33 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Baulac-2002" MODIFIED="2012-11-20 12:29:34 +0000" MODIFIED_BY="[Empty name]" NAME="Baulac 2002" TYPE="BOOK_SECTION">
<AU>Baulac M, Cramer JA, Mattson RH</AU>
<TI>Phenobarbital and other barbiturates: adverse effects</TI>
<SO>Antiepileptic Drugs</SO>
<YR>2002</YR>
<PG>528-40</PG>
<EN>5</EN>
<ED>Levy RH, Mattson RH, Meldrum BS, et al.</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bross-1958" MODIFIED="2012-11-20 13:28:33 +0000" MODIFIED_BY="[Empty name]" NAME="Bross 1958" TYPE="JOURNAL_ARTICLE">
<AU>Bross IDJ</AU>
<TI>How to use ridit analysis</TI>
<SO>Biometrics</SO>
<YR>1958</YR>
<VL>14</VL>
<PG>18-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EBCTCG-1990" MODIFIED="2012-11-20 12:30:48 +0000" MODIFIED_BY="[Empty name]" NAME="EBCTCG 1990" TYPE="BOOK">
<AU>Early Breast Cancer Trialists' Collaborative Group</AU>
<SO>Treatment of Early Breast Cancer, Worldwide Evidence, 1985-90</SO>
<YR>1990</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2012-06-21 17:21:52 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]</TI>
<SO>The Cochrane Collaboration</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ILAE-2006" MODIFIED="2012-11-20 12:31:18 +0000" MODIFIED_BY="[Empty name]" NAME="ILAE 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C et al</AU>
<TI>ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.</TI>
<SO>Epilepsia</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>7</NO>
<PG>1094-120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1996" MODIFIED="2012-11-20 12:31:10 +0000" MODIFIED_BY="Heather Maxwell" NAME="Jones 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jones B, Jarvis P, Lewis JA, Ebutt AF</AU>
<TI>Trials to assess equivalence; the importance of rigorous methods</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-2010" MODIFIED="2012-11-20 12:31:44 +0000" MODIFIED_BY="[Empty name]" NAME="Kirkham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R et al</AU>
<TI>The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c365</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2011-11-23 13:36:22 +0000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meador-2008" MODIFIED="2012-11-20 12:35:45 +0000" MODIFIED_BY="[Empty name]" NAME="Meador 2008" TYPE="JOURNAL_ARTICLE">
<AU>Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C</AU>
<TI>Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts</TI>
<SO>Epilepsy Research</SO>
<YR>2008</YR>
<VL>81</VL>
<NO>1</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2012-05-23 12:34:13 +0100" MODIFIED_BY="[Empty name]" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scheinfeld-2003" MODIFIED="2012-06-14 12:05:20 +0100" MODIFIED_BY="[Empty name]" NAME="Scheinfeld 2003" TYPE="JOURNAL_ARTICLE">
<AU>Scheinfeld N</AU>
<TI>Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects</TI>
<SO>Dermatology Online Journal</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>3</NO>
<PG>6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stata-2009" MODIFIED="2012-11-20 12:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Stata 2009" TYPE="COMPUTER_PROGRAM">
<AU>StataCorp</AU>
<TI>Stata Statistical Software: Release 11</TI>
<YR>2009</YR>
<PB>StataCorp LP</PB>
<CY>College Station, TX</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trimble-1988" MODIFIED="2012-11-20 12:31:57 +0000" MODIFIED_BY="[Empty name]" NAME="Trimble 1988" TYPE="JOURNAL_ARTICLE">
<AU>Trimble MR, Cull C</AU>
<TI>Children of school age: the influence of antiepileptic drugs on behavior and intellect</TI>
<SO>Epilepsia</SO>
<YR>1988</YR>
<VL>29</VL>
<NO>Suppl 3</NO>
<PG>S15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williamson-2002" MODIFIED="2012-11-20 12:32:03 +0000" MODIFIED_BY="[Empty name]" NAME="Williamson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Williamson PR, Tudur Smith C, Hutton JL, Marson AG</AU>
<TI>Aggregate data meta-analysis with time-to-event outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>3337-51</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-11-20 12:32:30 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Taylor-2001" MODIFIED="2012-11-20 12:32:30 +0000" MODIFIED_BY="[Empty name]" NAME="Taylor 2001" TYPE="COCHRANE_REVIEW">
<AU>Taylor S, Tudur Smith C, Williamson PR, Marson AG</AU>
<TI>Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-11-12 16:18:46 +0000" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2012-11-12 16:18:46 +0000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD002217"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-11-20 12:26:44 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-11-20 12:26:43 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-11-20 12:26:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cereghino-1974">
<CHAR_METHODS MODIFIED="2012-11-20 12:26:30 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over trial with 21 day treatment periods and 2-week washout period.</P>
<P>During washout period "regular medications" were used to allow participants to return to pre-trial state between periods. Unclear if "regular medications" included AEDs.</P>
<P>Randomly allocated using random number tables.</P>
<P>Method of allocation concealment not stated.</P>
<P>Double blind achieved using additional placebo capsules.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-20 12:26:31 +0000" MODIFIED_BY="[Empty name]">
<P>Institutionalised adult participants with uncontrolled seizures on current medication (unclear if pre-study regimen included AEDs).</P>
<P>Number randomised: PHT = 45, PB = 45.</P>
<P>41 participants (91%) with partial epilepsy.  28 (62%) male participants.  Age range: 18 - 51 years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-20 12:26:31 +0000" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT.<BR/>Daily study dose: PHT = 300 mg/day; PB = 300 mg/day.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-13 09:26:10 +0000" MODIFIED_BY="[Empty name]">
<P>Behaviour outcomes.</P>
<P>Adverse effects.</P>
<P>Seizure frequency.</P>
<P>Time to treatment withdrawal due to poor seizure control.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-20 12:26:33 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes chosen for this review were not reported due to cross-over design. Unclear if epilepsy was newly diagnosed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-20 12:26:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czapinski-1997">
<CHAR_METHODS MODIFIED="2012-11-20 12:26:34 +0000" MODIFIED_BY="[Empty name]">
<P>36-month randomised comparative study.</P>
<P>Method of generation of random list and allocation concealment not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-13 09:27:24 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with newly diagnosed epilepsy.</P>
<P>Number randomised: PB = 30; PHT = 30.</P>
<P>100% partial epilepsy, Age range: 18 to 40 years.</P>
<P>Percentage male and range of follow-up not mentioned.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-10 15:54:03 +0100" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT.</P>
<P>Starting doses PHT = 200 mg/day, PB = 100 mg/day. Dose achieved not stated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-13 09:27:29 +0000" MODIFIED_BY="[Empty name]">
<P>Proportion achieving 24-month remission at 3 years and exclusions after randomisation due to adverse effects or no efficacy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-25 13:35:24 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Outcomes chosen for this review were not reported. IPD pledged, but not received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 09:28:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Silva-1996">
<CHAR_METHODS MODIFIED="2012-11-13 09:28:06 +0000" MODIFIED_BY="[Empty name]">
<P>Random list generated using random permuted blocks.</P>
<P>Allocation concealed using sealed opaque envelopes.</P>
<P>Unblinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-13 09:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Children with newly diagnosed epilepsy (two or more untreated partial or generalised tonic clonic seizures in the 12 months preceding the study).</P>
<P>Number randomised: PB group = 10; PHT group = 54.<BR/>38 children (59%) with partial epilepsy. 35 (55%) male children. Mean age (range): 9 (3 to 16) years.<BR/>Range of follow-up 3 to 88 (months).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-23 09:00:26 +0100" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT.<BR/>Median daily dose achieved: PB = not stated due to withdrawal of treatment; PHT = 175 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-13 09:28:14 +0000" MODIFIED_BY="[Empty name]">
<P>Time to first seizure recurrence after start of therapy.</P>
<P>Time to 12-month remission from all seizures.</P>
<P>Adverse effects and withdrawals due to adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-23 09:05:04 +0100" MODIFIED_BY="[Empty name]">
<P>6 of the first 10 children assigned to PB had unacceptable adverse effects so no further children were assigned to PB. IPD provided for all outcomes of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-20 12:26:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gruber-1962">
<CHAR_METHODS MODIFIED="2012-11-20 12:26:34 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over trial with three one week treatment periods (5 days treatment, 2 days washout period, three separate doses of each drug).  </P>
<P>Drug doses administered according to a Latin square design. Method of allocation concealment not stated.</P>
<P>Double blind achieved using identical &#8220;blank&#8221; tablets.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-13 09:29:23 +0000" MODIFIED_BY="[Empty name]">
<P>Institutionalised adult participants with focal brain damage.</P>
<P>Number randomised: PB = 48; PHT = 48.</P>
<P>Proportion of participants with partial epilepsy, proportion of male participants and age range not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-23 09:10:29 +0100" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT.<BR/>Drug doses increased daily across period of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-13 09:29:32 +0000" MODIFIED_BY="[Empty name]">
<P>Number of seizures reported per patient day.</P>
<P>Seizure 'score' based on the number of seizures per patient per day (calculated by the method of ridit transformation (<LINK REF="REF-Bross-1958" TYPE="REFERENCE">Bross 1958</LINK>)).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-20 12:26:35 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes chosen for this review were not reported due to cross-over design. Unclear if seizures were newly diagnosed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 09:30:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heller-1995">
<CHAR_METHODS MODIFIED="2012-11-13 09:30:26 +0000" MODIFIED_BY="[Empty name]">
<P>Random list generated using random permuted blocks.</P>
<P>Allocation concealed using sealed opaque envelopes.</P>
<P>Unblinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-13 09:30:33 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with newly diagnosed epilepsy (two or more untreated partial or generalised tonic clonic seizures in the 12 months preceding the study).<BR/>Number randomised: PB group = 58; PHT group = 63.<BR/>53 participants (44%) with partial epilepsy. 59 (49%) male participants. Mean age (range): 34 (14 to 77) years.<BR/>Range of follow-up 1 to 91 (months).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-23 09:14:30 +0100" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT.<BR/>Median daily dose achieved: PB = 105 mg/day; PHT = 300 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-13 09:30:36 +0000" MODIFIED_BY="[Empty name]">
<P>Time to first seizure recurrence after start of therapy.</P>
<P>Time to 12-month remission from all seizures.</P>
<P>Adverse effects and withdrawals due to adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-13 09:30:38 +0000" MODIFIED_BY="[Empty name]">
<P>IPD provided for all outcomes of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-20 12:26:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattson-1985">
<CHAR_METHODS MODIFIED="2012-11-20 12:26:36 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised study with separate randomisation schemes used for each seizure type.</P>
<P>Method of generation of random list not stated. Allocation concealment achieved with sealed opaque envelopes.</P>
<P>Double blind achieved by providing additional blank tablet.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-13 09:31:12 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with previously untreated or under-treated simple or complex partial or secondary generalised tonic clonic seizures.<BR/>Number randomised: PB group = 155; PHT group = 165.<BR/>100% of participants had partial epilepsy. 88% of participants were male.<BR/>Mean age (range) 40 (18-81) years. Range of follow-up: 0-66 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 09:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT.<BR/>Median daily dose achieved: PHT = 400 mg/day; PB = 160mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-20 12:26:37 +0000" MODIFIED_BY="[Empty name]">
<P>Participant retention/time to drug failure (length of time participant continued to take randomised drug).</P>
<P>Composite scores of seizure frequency (seizure rates and total seizure control) and toxicity.</P>
<P>Incidence of side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-13 09:31:24 +0000" MODIFIED_BY="[Empty name]">
<P>IPD provided for all outcomes of this review. Proportions of "untreated" and "under treated" not known.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-20 12:26:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pal-1998">
<CHAR_METHODS MODIFIED="2012-11-13 09:33:07 +0000" MODIFIED_BY="[Empty name]">
<P>Participants randomised by prepared randomised number list and by minimisation.</P>
<P>Method of allocation concealment not stated.</P>
<P>Participants (and parents) and personnel unblinded, outcome assessor single blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-20 12:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>Children from a rural district of a developing country (India) who had experienced two or more unprovoked seizures within the 12 months preceding the study and had been untreated in the three months preceding the study.<BR/>Number randomised: PB group = 47 ; PHT group = 47.<BR/>
</P>
<P>60 children (64%) had partial epilepsy. 49 (52%) male children.</P>
<P>Mean age (range): 11(2 to 18) years.  Range of follow-up (months) 0-12.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-23 09:30:20 +0100" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT. </P>
<P>Maintenance doses: PHT 5 mg/kg/day, PB 3 mg/kg/day. Daily dose achieved not stated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-20 12:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>Time to first seizure.</P>
<P>Proportion seizure-free in each study quarter.</P>
<P>Proportion of adverse events including behavioural side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 15:53:07 +0100" MODIFIED_BY="[Empty name]">
<P>IPD provided for remission and seizure outcomes of this review. Withdrawal information not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-20 12:26:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thilothammal-1996">
<CHAR_METHODS MODIFIED="2012-11-20 12:26:40 +0000" MODIFIED_BY="[Empty name]">
<P>Random list generated using computer-generated random numbers. Method of concealment not mentioned.</P>
<P>Double-blind achieved by providing additional placebo tablets.               </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-20 12:26:41 +0000" MODIFIED_BY="[Empty name]">
<P>Children with more than one previously untreated generalised tonic clonic (afebrile) seizure.</P>
<P>Number randomised: PB group = 51 ; PHT group = 52.<BR/>0% partial epilepsy. 55 (53%) male children.</P>
<P>Age range: 4 to 12 years. Range of follow-up (months): 22 to 36.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-23 09:36:29 +0100" MODIFIED_BY="[Empty name]">
<P>Monotherapy with PB or PHT. Dose achieved not stated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-20 12:26:41 +0000" MODIFIED_BY="[Empty name]">
<P>Proportion with recurrence of seizures.</P>
<P>Adverse effects/side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-13 09:34:43 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes chosen for this review were not reported, IPD not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<SUP>1</SUP>Abbreviations</P>
<P>AEDS: antiepileptic drugs, IPD: individual participant data, ITT: Intention to treat, PB: phenobarbitone, PHT: phenytoin<BR/>
</P>
<P>
<SUP>2</SUP>For studies which IPD were provided (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>, <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>, <LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>, <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>) attrition and reporting bias are reduced as attrition rates and unpublished outcome data are requested</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-11-20 12:26:44 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-11-20 12:26:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bird-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-20 12:26:43 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear whether trial is randomised and unclear whether participants received PHT or PB as monotherapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cereghino-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Polytherapy comparisons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-20 12:26:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meador-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-20 12:26:44 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison between PHT and PB monotherapy cannot be made due to the cross-over trial design. Some participants were receiving treatment at the start of the first period which had to be withdrawn slowly.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-20 12:26:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verma-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-20 12:26:44 +0000" MODIFIED_BY="[Empty name]">
<P>Trial recruits neonatal infants with seizures due to birth complications (birth asphyxia) rather than epilepsy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-White-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Polytherapy comparisons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PB: phenobarbitone, PHT: phenytoin</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-11-24 16:02:29 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-11-20 12:26:42 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-11-20 12:26:42 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 08:56:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cereghino-1974">
<DESCRIPTION>
<P>Randomisation of groups from random number tables (confirmed by author)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-14 15:11:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czapinski-1997">
<DESCRIPTION>
<P>Study "randomised" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:12:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruber-1962">
<DESCRIPTION>
<P>Drug doses were administered according to a Latin square design, no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-24 16:00:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heller-1995">
<DESCRIPTION>
<P>Randomisation list generated using permuted blocks of size 8 or 16 with stratification for centre, seizure type and presence of neurological signs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:28:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattson-1985">
<DESCRIPTION>
<P>Participants randomised with stratification for seizure type. Method of generation of random list not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 12:26:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pal-1998">
<DESCRIPTION>
<P>First 10 participants randomised from a pre-prepared balanced random number list, following participants randomised by minimisation with stratification by age group and presence of cerebral impairment  </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 12:26:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thilothammal-1996">
<DESCRIPTION>
<P>Participants randomised via a computer-generated list of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Silva-1996">
<DESCRIPTION>
<P>Randomisation list generated using permuted blocks of size 8 or 16 with stratification for centre, seizure type and presence of neurological signs </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-18 18:37:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 11:52:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cereghino-1974">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-28 14:00:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czapinski-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:12:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruber-1962">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-24 16:01:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heller-1995">
<DESCRIPTION>
<P>Allocation concealed via 4 batches of concealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-18 18:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mattson-1985">
<DESCRIPTION>
<P>Allocation concealment achieved with sealed opaque envelopes (information provided by author) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:35:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pal-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 13:30:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thilothammal-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-24 15:59:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Silva-1996">
<DESCRIPTION>
<P>Allocation concealed via 4 batches of concealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-11-20 12:26:40 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-25 11:52:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cereghino-1974">
<DESCRIPTION>
<P>Double-blinded (participants and personnel) using additional placebo capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-28 14:00:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czapinski-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-18 18:57:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gruber-1962">
<DESCRIPTION>
<P>Double blind (participants and personnel) achieved using an additional blank tablet </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-29 15:55:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heller-1995">
<DESCRIPTION>
<P>Unblinded, authors state masking of treatment would not be &#8220;practical&#8221; and would have &#8220;introduced bias due to a very large drop-out rate.&#8221; Lack of blinding may have lead to more withdrawals of PB</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-25 11:54:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mattson-1985">
<DESCRIPTION>
<P>Double-blinded (participants and personnel) using additional blank tablet</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-20 12:26:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pal-1998">
<DESCRIPTION>
<P>Participants, parents and treating physicians unblinded for &#8220;practical and ethical reasons.&#8221; Outcome assessors single-blinded. Withdrawal information from treatments not available, however lack of blinding may have influenced withdrawal rates</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-25 13:31:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thilothammal-1996">
<DESCRIPTION>
<P>Double-blinded (participants and personnel) using additional placebo tablets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-23 09:01:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Silva-1996">
<DESCRIPTION>
<P>Unblinded, authors state masking of treatment would not be &#8220;practicable or ethical&#8221; and would &#8220;undermine compliance.&#8221; Lack of masking could have led to early withdrawal of PB from the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-06-18 18:57:38 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-23 08:56:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cereghino-1974">
<DESCRIPTION>
<P>Withdrawal rates reported, no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 10:03:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czapinski-1997">
<DESCRIPTION>
<P>"Exclusion rates" (interpreted as withdrawal rates) reported for all treatment groups, no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-23 09:13:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruber-1962">
<DESCRIPTION>
<P>Attrition rates reported, no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-18 18:57:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heller-1995">
<DESCRIPTION>
<P>Attrition rates reported, all randomised participants analyses from IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-18 18:57:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mattson-1985">
<DESCRIPTION>
<P>Attrition rates reported, all randomised participants analysed from IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-18 18:57:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pal-1998">
<DESCRIPTION>
<P>Attrition rates reported, all randomised participants analysed from IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-18 18:57:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thilothammal-1996">
<DESCRIPTION>
<P>Attrition rates reported, all randomised participants analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-18 18:56:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Silva-1996">
<DESCRIPTION>
<P>Attrition rates reported, all randomised participants analyses from IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-11-20 12:26:36 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 12:26:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cereghino-1974">
<DESCRIPTION>
<P>No protocol available, outcomes for this review not available due to trial cross-over design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:05:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czapinski-1997">
<DESCRIPTION>
<P>No protocol available and study reported only in abstract form, outcomes for this review not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 12:26:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruber-1962">
<DESCRIPTION>
<P>No protocol available, outcomes for this review not available due to cross-over design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heller-1995">
<DESCRIPTION>
<P>All outcomes reported or calculated with IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 11:54:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mattson-1985">
<DESCRIPTION>
<P>All outcomes reported or calculated with IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:35:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pal-1998">
<DESCRIPTION>
<P>All outcomes reported or calculated with IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thilothammal-1996">
<DESCRIPTION>
<P>No protocol available, outcomes chosen for this review not reported, main outcomes (seizure reduction and adverse effects) adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-23 09:02:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Silva-1996">
<DESCRIPTION>
<P>All outcomes reported or calculated with IPD provided (see footnote 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2012-06-18 18:46:35 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Other Bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:04:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cereghino-1974">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:06:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czapinski-1997">
<DESCRIPTION>
<P>Insufficient detail provided in abstract to allow judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:08:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gruber-1962">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:08:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heller-1995">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:08:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mattson-1985">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-18 18:46:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pal-1998">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:11:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thilothammal-1996">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-14 15:31:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Silva-1996">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-11-20 12:26:58 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-11-20 12:26:58 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-30 08:15:01 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD COLSPAN="7">
<P>
<B>Phenobarbitone compared with phenytoin for Epilepsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>adults and children with newly diagnosed partial onset or generalised onset seizures</P>
<P>
<B>Settings: </B>Outpatients</P>
<P>
<B>Intervention: </B>Phenobarbitone</P>
<P>
<B>Comparison: </B>Phenytoin</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Phenytoin</P>
</TH>
<TH VALIGN="TOP">
<P>Phenobarbitone</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to treatment withdrawal - all participants</B>
</P>
<P>Range of follow-up (all participants): 1 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>36 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>52 per 100</B>
<BR/>(42 to 62)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 1.62 </B>(1.23 to 2.14)<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>499<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>2,3</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenytoin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to treatment withdrawal - stratified by seizure type - Generalised seizures</B>
</P>
<P>Range of follow-up (all participants):1 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>14 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>46 per 100</B>
<BR/>(22 to 78)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 4.04 </B>(1.61 to 10.14)</P>
</TD>
<TD VALIGN="TOP">
<P>95<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>2,4</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenytoin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to treatment withdrawal - stratified by seizure type - Partial onset</B>
</P>
<P>Range of follow-up (all participants):1 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>42 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>56 per 100</B>
<BR/>(45 to 66)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 1.48</B> (1.10 to 1.98)</P>
</TD>
<TD VALIGN="TOP">
<P>404</P>
<P>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>2,3</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenytoin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to 12-month remission - all participants</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>48 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>45 per 100</B>
<BR/>(36 to 54)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.90 </B>(0.69 to 1.19)<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>599<BR/>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenobarbitone</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to 12-month remission - stratified by seizure type - Generalised seizures</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>71 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>61 per 100</B>
<BR/>(43 to 79)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.77 </B>(0.46 to 1.28)</P>
</TD>
<TD VALIGN="TOP">
<P>131<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenobarbitone</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to 12-month remission - stratified by seizure type - Partial Onset</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>42 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>40 per 100</B>
<BR/>(31 to 51)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.96 </B>(0.70 to 1.33)</P>
</TD>
<TD VALIGN="TOP">
<P>468<BR/>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenobarbitone</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to 6-month remission - all participants</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>59 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>55 per 100</B>
<BR/>(47 to 64)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.90 </B>(0.71 to 1.14)<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>599<BR/>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenobarbitone</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to 6-month remission - stratified by seizure type - Generalised seizures</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>82 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>74 per 100</B>
<BR/>(58 to 88)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.79 </B>(0.51 to 1.24)</P>
</TD>
<TD VALIGN="TOP">
<P>131<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenobarbitone</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to 6-month remission - stratified by seizure type - Partial onset</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>53 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>50 per 100</B>
<BR/>(41 to 61)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.94 </B>(0.71 to 1.25)</P>
</TD>
<TD VALIGN="TOP">
<P>468<BR/>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenobarbitone</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to first seizure - all participants</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>66 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>60 per 100</B>
<BR/>(52 to 68)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.86 </B>(0.69 to 1.08)<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>592</P>
<P>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenytoin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to first seizure - stratified by epilepsy type - Generalised seizures</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>71 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>75 per 100</B>
<BR/>(59 to 89)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 1.14</B> (0.73 to 1.78)</P>
</TD>
<TD VALIGN="TOP">
<P>131<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenytoin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Time to first seizure - stratified by epilepsy type - Partial onset</B>
</P>
<P>Range of follow-up (all participants): 0 to 91 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>64 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>55 per 100</B>
<BR/>(46 to 65)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HR 0.78 </B>(0.61 to 1.01)</P>
</TD>
<TD VALIGN="TOP">
<P>461<BR/>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR&gt;1 indicates a clinical advantage for phenytoin</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the Phenytoin treatment group</P>
<P>The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P>
<P>The corresponding risk is calculated as the assumed risk x the relative risk (RR) of the intervention where RR = (1 - exp(HR x ln(1 - assumed risk)) ) / assumed risk</P>
<P>
<B>CI:</B> Confidence interval; <B>RR: </B>relative risk; <B>HR:</B> Hazard Ratio; <B>exp: </B>exponential</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Pooled Hazard Ratio for all participants adjusted for seizure type</P>
<P>
<SUP>2 </SUP>Risk of Bias judged as high for three unblinded studies (<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>; <LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>; <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>) as lack of masking may have influenced the withdrawal rates of phenobarbitone</P>
<P>
<SUP>3</SUP> Substantial heterogeneity present between studies</P>
<P>
<SUP>4</SUP>Large confidence intervals around the summary estimate</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-11-20 12:27:59 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-11-20 12:27:08 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-23 11:38:51 +0100" MODIFIED_BY="[Empty name]">Outcomes considered and summary of results for trials with no IPD</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Trial</P>
<P> </P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Number Randomised</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Outcomes Reported</P>
<P> </P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Summary of Results </P>
<P> </P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>PB</P>
</TH>
<TH VALIGN="TOP">
<P>PHT</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cereghino-1974" TYPE="STUDY">Cereghino 1974</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>1. Behaviour measured with rating scale modified from the Ward Behaviour Rating Scale</P>
<P>2. Seizure Control</P>
<P>3. Side Effects</P>
<P>4. Withdrawals</P>
</TD>
<TD VALIGN="TOP">
<P>1. No change or improvement in behaviour is more common on PB than PHT (68% vs 37%)</P>
<P>Deterioration of behaviour more common on PHT than PB (32% vs 20%)</P>
<P>2. No difference between PB and PHT in terms of seizure control.</P>
<P>3. Side effects were minimal on both drugs</P>
<P>4. PB: 26 withdrawals out of 44 participants (59%)</P>
<P>PHT 21 withdrawals out of 45 participants (47%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Czapinski-1997" TYPE="STUDY">Czapinski 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1. Proportion achieving 24-month remission at 3 years</P>
<P>2. Proportion "excluded" after randomisation due to adverse effects or no efficacy</P>
</TD>
<TD VALIGN="TOP">
<P>1. PB: 60% PHT: 59%</P>
<P>2. PB: 33% PHT: 23%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gruber-1962" TYPE="STUDY">Gruber 1962</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>Seizure score</P>
</TD>
<TD VALIGN="TOP">
<P>Score of PHT is double the score of PB</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Thilothammal-1996" TYPE="STUDY">Thilothammal 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>1. Recurrence of Seizures</P>
<P>2. Side Effects</P>
</TD>
<TD VALIGN="TOP">
<P>1. PB:16 out of 51 participants (31%) PHT: 14 out of 52 participants (27%)</P>
<P>2. PB:17 out of 51 participants (33%) PHT: 33 out of 52 participants (63%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PB: phenobarbitone, PHT: phenytoin</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-11-20 12:27:12 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-06-18 18:59:52 +0100" MODIFIED_BY="[Empty name]">Number of participants contributing to analysis - stratified by epilepsy type</TITLE>
<TABLE COLS="10" ROWS="15">
<TR>
<TH ROWSPAN="2">
<P>Trial</P>
</TH>
<TH ROWSPAN="2">
<P>Epilepsy Type</P>
</TH>
<TH COLSPAN="2">
<P>Number randomised</P>
</TH>
<TH COLSPAN="2">
<P>Time to 6-month and</P>
<P>12-month remission</P>
</TH>
<TH COLSPAN="2">
<P>Time to 1st seizure</P>
</TH>
<TH COLSPAN="2">
<P>Time to Withdrawal</P>
</TH>
</TR>
<TR>
<TH>
<P>PB</P>
</TH>
<TH>
<P>PHT</P>
</TH>
<TH>
<P>PB</P>
</TH>
<TH>
<P>PHT</P>
</TH>
<TH>
<P>PB</P>
</TH>
<TH>
<P>PHT</P>
</TH>
<TH>
<P>PB</P>
</TH>
<TH>
<P>PHT</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>
</P>
</TD>
<TD>
<P>Partial</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
<TR>
<TD>
<P>Generalised</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Total Classified</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>53</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Heller-1995" TYPE="STUDY">Heller 1995</LINK>
</P>
</TD>
<TD>
<P>Partial</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>Generalised</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>34</P>
</TD>
</TR>
<TR>
<TD>
<P>Total Classified</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Mattson-1985" TYPE="STUDY">Mattson 1985</LINK>
</P>
</TD>
<TD>
<P>Partial</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>165</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>165</P>
</TD>
<TD>
<P>151</P>
</TD>
<TD>
<P>162</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>165</P>
</TD>
</TR>
<TR>
<TD>
<P>Generalised</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Total Classified</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>165</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>165</P>
</TD>
<TD>
<P>151</P>
</TD>
<TD>
<P>162</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>165</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK>
</P>
</TD>
<TD>
<P>Partial</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Generalised</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Total Classified</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>TOTAL</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>270</P>
</TD>
<TD>
<P>329</P>
</TD>
<TD>
<P>270</P>
</TD>
<TD>
<P>329</P>
</TD>
<TD>
<P>266</P>
</TD>
<TD>
<P>326</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>279</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Classifications of seizure type were provided for all participants from individual participant data</P>
<P>N/A: For <LINK REF="STD-Pal-1998" TYPE="STUDY">Pal 1998</LINK> information on time to withdrawal from allocated drug is not available<BR/>
<BR/>PB: phenobarbitone, PHT: phenytoin<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2012-11-20 12:27:17 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Stratified logrank analysis</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TH>
<P>Test for:</P>
</TH>
<TH>
<P>Statistic</P>
</TH>
<TH>
<P>Time to Withdrawal*</P>
</TH>
<TH>
<P>Time to 12-month</P>
<P>remission</P>
</TH>
<TH>
<P>Time to 6-month</P>
<P>remission</P>
</TH>
<TH>
<P>Time to First seizure</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Heterogenity (unstratified)</P>
</TD>
<TD>
<P>Chi<SUP>2</SUP>
</P>
</TD>
<TD>
<P>(df = 2) 6.68</P>
</TD>
<TD>
<P>(df = 3) 1.17</P>
</TD>
<TD>
<P>(df = 3) 2.15</P>
</TD>
<TD>
<P>(df = 3) 2.80</P>
</TD>
</TR>
<TR>
<TD>
<P>P value</P>
</TD>
<TD>
<P>0.04</P>
</TD>
<TD>
<P>0.76</P>
</TD>
<TD>
<P>0.54</P>
</TD>
<TD>
<P>0.42</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Overall effect (unstratified)</P>
</TD>
<TD>
<P>Chi<SUP>2</SUP>
</P>
</TD>
<TD>
<P>(df = 1) 7.55</P>
</TD>
<TD>
<P>(df = 1) 0.60</P>
</TD>
<TD>
<P>(df = 1) 0.52</P>
</TD>
<TD>
<P>(df = 1) 2.17</P>
</TD>
</TR>
<TR>
<TD>
<P>P value</P>
</TD>
<TD>
<P>0.006</P>
</TD>
<TD>
<P>0.44</P>
</TD>
<TD>
<P>0.47</P>
</TD>
<TD>
<P>0.14</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Interaction between treatment</P>
<P>and seizure type</P>
</TD>
<TD>
<P>Chi<SUP>2</SUP>
</P>
</TD>
<TD>
<P>(df = 1) 4.18</P>
</TD>
<TD>
<P>(df = 1) 0.53</P>
</TD>
<TD>
<P>(df = 1) 0.43</P>
</TD>
<TD>
<P>(df = 1) 2.04</P>
</TD>
</TR>
<TR>
<TD>
<P>P value</P>
</TD>
<TD>
<P>0.04</P>
</TD>
<TD>
<P>0.47</P>
</TD>
<TD>
<P>0.51</P>
</TD>
<TD>
<P>0.15</P>
</TD>
</TR>
<TR>
<TD>
<P>Hazard ratio (95% CI)</P>
<P>adjusted for seizure type</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.62 (1.23-2.14)</P>
</TD>
<TD>
<P>0.90 (0.69-1.19)</P>
</TD>
<TD>
<P>0.90 (0.71 - 1.14)</P>
</TD>
<TD>
<P>0.86 (0.69 - 1.08)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Results are presented as pooled hazard ratios with 95% Confidence intervals, calculated with fixed effects</P>
<P>*Random effects estimates also calculated for Time to Withdrawal as substantial heterogeneity is present (see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2012-11-20 12:27:59 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-12-20 13:16:33 +0000" MODIFIED_BY="[Empty name]">Sensitivity analysis for de Silva 1996 trial</TITLE>
<TABLE COLS="5" ROWS="9">
<TR>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P>Time to withdrawal</P>
</TH>
<TH VALIGN="TOP">
<P>Time to 12-month remission</P>
</TH>
<TH VALIGN="TOP">
<P>Time to six-month remission</P>
</TH>
<TH VALIGN="TOP">
<P>Time to first seizure</P>
</TH>
</TR>
<TR>
<TD>
<P>Number randomised: O (P/G)</P>
</TD>
<TD>
<P>PHB: 10 (5/5)</P>
<P>PHT: 53 (30/23)</P>
</TD>
<TD>
<P>PHB: 10 (5/5)</P>
<P>PHT: 54 (30/24)</P>
</TD>
<TD>
<P>PHB: 10 (5/5)</P>
<P>PHT: 54 (30/24)</P>
</TD>
<TD>
<P>PHB: 10 (5/5)</P>
<P>PHT: 54 (30/24)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(i) original analysis</P>
</TD>
<TD VALIGN="TOP">
<P>P: 1.48 (1.10, 1.98) P value = 0.009</P>
<P>G: 4.04 (1.61, 10.14) P value = 0.003</P>
<P>O: 1.62 (1.23, 2.14) P value = 0.0007</P>
</TD>
<TD VALIGN="TOP">
<P>P: 0.98 (0.71, 1.36) P value = 0.92</P>
<P>G: 0.81 (0.50, 1.33) P value = 0.41</P>
<P>O: 0.93 (0.71, 1.21) P value = 0.59</P>
</TD>
<TD VALIGN="TOP">
<P>P: 0.94 (0.71, 1.25) P value = 0.69</P>
<P>G: 0.79 (0.51, 1.24) P value = 0.31</P>
<P>O: 0.90 (0.71, 1.14) P value = 0.38</P>
</TD>
<TD VALIGN="TOP">
<P>P: 0.78 (0.61, 1.01) P value = 0.06</P>
<P>G: 1.14 (0.73, 1.78) P value = 0.56</P>
<P>O: 0.86 (0.69, 1.08) P value = 0.19</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(i) Test of interaction</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> = 5.18 df = 1</P>
<P>P value = 0.02</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> = 0.41 df = 1</P>
<P>P value = 0.52</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> =0.43 df = 1</P>
<P>P value = 0.51</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> = 2.04 df = 1</P>
<P>P value = 0.15</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number included in sensitivity analysis (ii)</P>
</TD>
<TD VALIGN="TOP">
<P>PHB: 10 (5/5)</P>
<P>PHT: 7 (5/2)</P>
</TD>
<TD VALIGN="TOP">
<P>PHB: 10 (5/5)</P>
<P>PHT: 7 (5/2)</P>
</TD>
<TD VALIGN="TOP">
<P>PHB: 10 (5/5)</P>
<P>PHT: 7 (5/2)</P>
</TD>
<TD VALIGN="TOP">
<P>PHB: 10 (5/5)</P>
<P>PHT: 7 (5/2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(ii) sensitivity analysis with PHT randomised</P>
<P>after PB discontinued excluded</P>
</TD>
<TD VALIGN="TOP">
<P>P: 1.54 (1.03, 2.30) P value = 0.04</P>
<P>G: 4.01 (1.29, 12.40) P value = 0.02</P>
<P>O: 1.89 (1.15, 3.09) P value = 0.01</P>
</TD>
<TD VALIGN="TOP">
<P>P: 0.88 (0.63, 1.24) P value = 0.34</P>
<P>G: 0.77 (0.45, 1.31) P value = 0.47</P>
<P>O: 0.85 (0.64, 1.13) P value = 0.26</P>
</TD>
<TD VALIGN="TOP">
<P>P: 0.89 (0.67, 1.19) P value<I> </I>= 0.43</P>
<P>G: 0.80 (0.51, 1.27) P value<I> </I>= 0.35</P>
<P>O: 0.86 (0.68, 1.10) P value<I> </I>= 0.24</P>
</TD>
<TD VALIGN="TOP">
<P>P: 0.81 (0.62, 1.05) P value = 0.11</P>
<P>G: 1.06 (0.67, 1.69) P value = 0.80</P>
<P>O: 0.86 (0.69, 1.09) P value = 0.21</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(ii) Test of Interaction</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> = 2.45 df = 1</P>
<P>P value = 0.12</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> = 0.17 df = 1</P>
<P>P value = 0.68</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> = 0.14 df = 1</P>
<P>P value = 0.71</P>
</TD>
<TD VALIGN="TOP">
<P>Chi<SUP>2</SUP> = 1.00 df = 1</P>
<P>P value = 0.32</P>
</TD>
</TR>
<TR>
<TD>
<P>(iii) sensitivity analysis with <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK>
</P>
<P>excluded</P>
</TD>
<TD>
<P>P: 1.54 (1.03, 2.30) P = 0.04</P>
<P>G: 4.42 (1.23, 15.87) P = 0.02</P>
<P>O: 1.47 (1.09, 1.96) P = 0.01</P>
</TD>
<TD>
<P>P: 0.91 (0.65, 1.29) P value = 0.61</P>
<P>G: 0.86 (0.49, 1.50) P value = 0.59</P>
<P>O: 0.90 (0.67, 1.21) P value = 0.47</P>
</TD>
<TD>
<P>P: 0.91 (0.68, 1.22) P value<I> </I>= 0.52</P>
<P>G: 0.86 (0.53, 1.38) P value<I> </I>= 0.52</P>
<P>O: 0.89 (0.70, 1.15) P value<I> </I>= 0.37</P>
</TD>
<TD>
<P>P: 0.80 (0.61, 1.04) P value<I> </I>= 0.10</P>
<P>G: 0.97 (0.60, 1.59) P value<I> </I>= 0.92</P>
<P>O: 0.84 (0.66, 1.05) P value<I> </I>= 0.13</P>
</TD>
</TR>
<TR>
<TD>
<P>(iii) Test of interaction</P>
</TD>
<TD>
<P>Chi<SUP>2</SUP> = 3.03 df = 1</P>
<P>P value = 0.08</P>
</TD>
<TD>
<P>Chi<SUP>2</SUP> = 0.04 df = 1</P>
<P>P value = 0.85</P>
</TD>
<TD>
<P>Chi<SUP>2</SUP> = 0.04 df = 1</P>
<P>P value = 0.83</P>
</TD>
<TD>
<P>Chi<SUP>2</SUP> = 0.48 df = 1</P>
<P>P value = 0.49</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>P: Partial onset seizures, G: Generalised onset seizures O: Overall<BR/>PB: phenobarbitone, PHT: phenytoin<BR/>
</P>
<P>Analysis results are presented as pooled hazard ratios with 95% Confidence intervals, calculated with fixed effects and a P<I> </I>value for test of overall treatment effect</P>
<P>The test of interaction tests for an interaction between treatment effect and epilepsy type</P>
<P>In the <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> trial, PHB was discontinued after 10 children were randomised due to adverse events.</P>
<P>In (ii) those randomised to PHT after PB was discontinued are excluded in (iii) <LINK REF="STD-de-Silva-1996" TYPE="STUDY">de Silva 1996</LINK> trial is excluded</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-11-20 12:34:59 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-11-20 12:34:59 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Phenobarbitone versus phenytoin</NAME>
<IV_OUTCOME CHI2="6.67512089851834" CI_END="2.1370963762258044" CI_START="1.232588125017571" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.6230094316897883" ESTIMABLE="YES" I2="70.03799585946174" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.3298241079007381" LOG_CI_START="0.0908179793412861" LOG_DATA="YES" LOG_EFFECT_SIZE="0.21032104362101206" MODIFIED="2012-06-12 11:16:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03552361027056383" P_Q="1.0" P_Z="5.616979649204172E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="279" WEIGHT="100.00000000000001" Z="3.449465276665679">
<NAME>Time to treatment withdrawal</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PHT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="9.340215220474079" CI_START="1.6540233356995704" EFFECT_SIZE="3.930513189790926" ESTIMABLE="YES" ESTIMATE="1.36877" LOG_CI_END="0.9703568835092586" LOG_CI_START="0.2185416324801693" LOG_EFFECT_SIZE="0.594449257994714" MODIFIED="2012-06-12 11:16:39 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SE="0.44162" STUDY_ID="STD-de-Silva-1996" TOTAL_1="10" TOTAL_2="53" WEIGHT="10.106384373391066"/>
<IV_DATA CI_END="4.837322941297325" CI_START="1.1824381594830005" EFFECT_SIZE="2.3916177026298544" ESTIMABLE="YES" ESTIMATE="0.87197" LOG_CI_END="0.6846050820011657" LOG_CI_START="0.07277843676919143" LOG_EFFECT_SIZE="0.3786917593851785" MODIFIED="2012-05-18 13:35:06 +0100" MODIFIED_BY="[Empty name]" ORDER="94" SE="0.35939" STUDY_ID="STD-Heller-1995" TOTAL_1="55" TOTAL_2="61" WEIGHT="15.260237789730976"/>
<IV_DATA CI_END="1.8289714270710111" CI_START="0.9672737349366459" EFFECT_SIZE="1.3300812093084333" ESTIMABLE="YES" ESTIMATE="0.28524" LOG_CI_END="0.2622069208059298" LOG_CI_START="-0.014450604769762685" LOG_EFFECT_SIZE="0.12387815801808356" MODIFIED="2012-05-18 13:35:10 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SE="0.16251" STUDY_ID="STD-Mattson-1985" TOTAL_1="155" TOTAL_2="165" WEIGHT="74.63337783687797"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="8.361626588535325" CI_END="2.137971504021168" CI_START="1.2269033254307744" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="1.6195938836510235" ESTIMABLE="YES" I2="52.1624177108743" I2_Q="76.05092662250176" ID="CMP-001.02" LOG_CI_END="0.3300019124121244" LOG_CI_START="0.08881034358597968" LOG_DATA="YES" LOG_EFFECT_SIZE="0.209406127999052" MODIFIED="2012-11-20 12:33:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07919437777382043" P_Q="0.04101193817666249" P_Z="6.656736385917959E-4" Q="4.1755268950804885" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="279" WEIGHT="100.00000000000001" Z="3.4033401002998653">
<NAME>Time to treatment withdrawal - stratified by seizure type</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PHT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.039429170574927404" CI_END="10.144392211753093" CI_START="1.6106298896613827" DF="1" EFFECT_SIZE="4.04213573605559" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.006226031952014" LOG_CI_START="0.2069957543581439" LOG_EFFECT_SIZE="0.6066108931550788" MODIFIED="2012-11-20 12:33:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8426009361798186" P_Z="0.002927962883257941" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="57" WEIGHT="9.10710593932111" Z="2.9752013569680824">
<NAME>Generalised seizures</NAME>
<IV_DATA CI_END="13.817507344505813" CI_START="0.9745139586166273" EFFECT_SIZE="3.6695168320241676" ESTIMABLE="YES" ESTIMATE="1.30006" LOG_CI_END="1.1404297040971274" LOG_CI_START="-0.011211935810844217" LOG_EFFECT_SIZE="0.5646088841431416" MODIFIED="2012-05-18 14:19:33 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SE="0.67648" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="23" WEIGHT="4.3862110658024145"/>
<IV_DATA CI_END="15.87338989597138" CI_START="1.2319716878928442" EFFECT_SIZE="4.422167674650191" ESTIMABLE="YES" ESTIMATE="1.48663" LOG_CI_END="1.2006696839005102" LOG_CI_START="0.09060072736315229" LOG_EFFECT_SIZE="0.6456352056318312" MODIFIED="2012-05-17 09:53:13 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SE="0.65206" STUDY_ID="STD-Heller-1995" TOTAL_1="33" TOTAL_2="34" WEIGHT="4.720894873518696"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.146670522879907" CI_END="1.977429401875962" CI_START="1.1043699935980766" DF="2" EFFECT_SIZE="1.477773222077868" ESTIMABLE="YES" I2="51.768533599072185" ID="CMP-001.02.02" LOG_CI_END="0.29610098727817746" LOG_CI_START="0.0431145980832941" LOG_EFFECT_SIZE="0.16960779268073573" MODIFIED="2012-06-12 11:16:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12576566553460478" P_Z="0.008588642038580821" STUDIES="3" TAU2="0.0" TOTAL_1="182" TOTAL_2="222" WEIGHT="90.8928940606789" Z="2.6280082988614915">
<NAME>Partial onset</NAME>
<IV_DATA CI_END="16.681742135790262" CI_START="1.4002981299734407" EFFECT_SIZE="4.833157592862689" ESTIMABLE="YES" ESTIMATE="1.5755" LOG_CI_END="1.222241403642955" LOG_CI_START="0.14622050883419138" LOG_EFFECT_SIZE="0.6842309562385732" MODIFIED="2012-06-12 11:16:53 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SE="0.63206" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="30" WEIGHT="5.0243841300027405"/>
<IV_DATA CI_END="4.403632433566595" CI_START="0.7513754990610306" EFFECT_SIZE="1.8190056397527858" ESTIMABLE="YES" ESTIMATE="0.59829" LOG_CI_END="0.643811061722118" LOG_CI_START="-0.124142970566325" LOG_EFFECT_SIZE="0.2598340455778965" MODIFIED="2011-12-19 16:03:38 +0000" MODIFIED_BY="[Empty name]" ORDER="108" SE="0.4511" STUDY_ID="STD-Heller-1995" TOTAL_1="22" TOTAL_2="27" WEIGHT="9.864016603579175"/>
<IV_DATA CI_END="1.8289714270710111" CI_START="0.9672737349366459" EFFECT_SIZE="1.3300812093084333" ESTIMABLE="YES" ESTIMATE="0.28524" LOG_CI_END="0.2622069208059298" LOG_CI_START="-0.014450604769762685" LOG_EFFECT_SIZE="0.12387815801808356" MODIFIED="2011-12-19 16:03:37 +0000" MODIFIED_BY="[Empty name]" ORDER="109" SE="0.16251" STUDY_ID="STD-Mattson-1985" TOTAL_1="155" TOTAL_2="165" WEIGHT="76.00449332709698"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.1688359218430464" CI_END="1.1763041531707559" CI_START="0.6862805466291555" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.8984846449662743" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.07051963038377083" LOG_CI_START="-0.16349831148577026" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04648934055099976" MODIFIED="2012-05-29 15:52:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7604880845134748" P_Q="1.0" P_Z="0.4361436349095624" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="270" TOTAL_2="329" WEIGHT="100.0" Z="0.7787217716475137">
<NAME>Time to 12-month remission from seizures</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.7766094212451442" CI_START="0.4190409092841482" EFFECT_SIZE="0.8628279245141233" ESTIMABLE="YES" ESTIMATE="-0.14754" LOG_CI_END="0.24959196081466858" LOG_CI_START="-0.3777435765346802" LOG_EFFECT_SIZE="-0.06407580786000579" MODIFIED="2011-12-20 13:06:22 +0000" MODIFIED_BY="[Empty name]" ORDER="97" SE="0.3685" STUDY_ID="STD-de-Silva-1996" TOTAL_1="10" TOTAL_2="54" WEIGHT="13.915490868612693"/>
<IV_DATA CI_END="1.4017149658428367" CI_START="0.5908361969269793" EFFECT_SIZE="0.9100461194874754" ESTIMABLE="YES" ESTIMATE="-0.09426" LOG_CI_END="0.1466597102449216" LOG_CI_START="-0.2285329059733226" LOG_EFFECT_SIZE="-0.04093659786420051" MODIFIED="2011-12-19 13:02:32 +0000" MODIFIED_BY="[Empty name]" ORDER="99" SE="0.22039" STUDY_ID="STD-Heller-1995" TOTAL_1="58" TOTAL_2="63" WEIGHT="38.903595880441216"/>
<IV_DATA CI_END="1.2725333867923312" CI_START="0.562924531856658" EFFECT_SIZE="0.8463688681845762" ESTIMABLE="YES" ESTIMATE="-0.1668" LOG_CI_END="0.10466918551525271" LOG_CI_START="-0.24954982467817755" LOG_EFFECT_SIZE="-0.07244031958146241" MODIFIED="2011-12-19 16:33:48 +0000" MODIFIED_BY="[Empty name]" ORDER="98" SE="0.20807" STUDY_ID="STD-Mattson-1985" TOTAL_1="155" TOTAL_2="165" WEIGHT="43.64701830297707"/>
<IV_DATA CI_END="8.027587637286194" CI_START="0.4567934022957969" EFFECT_SIZE="1.9149279540138415" ESTIMABLE="YES" ESTIMATE="0.64968" LOG_CI_END="0.904585055463336" LOG_CI_START="-0.34028017745752664" LOG_EFFECT_SIZE="0.28215243900290465" MODIFIED="2012-05-17 11:05:26 +0100" MODIFIED_BY="[Empty name]" ORDER="100" SE="0.73124" STUDY_ID="STD-Pal-1998" TOTAL_1="47" TOTAL_2="47" WEIGHT="3.533894947969032"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.664824553652777" CI_END="1.1875026198846346" CI_START="0.68606625387159" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.9026103665962131" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.07463457644442831" LOG_CI_START="-0.16363394216286292" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04449968285921726" MODIFIED="2012-11-20 12:34:04 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5874624800577988" P_Q="0.46504252628811205" P_Z="0.4641096680603013" Q="0.5337310774614521" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="270" TOTAL_2="329" WEIGHT="99.99999999999999" Z="0.7320965122653961">
<NAME>Time to 12 month remission - stratified by seizure type</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.8291689899656629" CI_END="1.2811039382139269" CI_START="0.46122208436386486" DF="2" EFFECT_SIZE="0.768682918159226" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.10758436624865386" LOG_CI_START="-0.33608990587053694" LOG_EFFECT_SIZE="-0.11425276981094155" MODIFIED="2012-11-20 12:34:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6606147274015531" P_Z="0.3127636005263036" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="72" WEIGHT="28.84063633738242" Z="1.0094401593033218">
<NAME>Generalised seizures</NAME>
<IV_DATA CI_END="1.5572009635510486" CI_START="0.13533934937515882" EFFECT_SIZE="0.45907577288871315" ESTIMABLE="YES" ESTIMATE="-0.77854" LOG_CI_END="0.1923446637751084" LOG_CI_START="-0.8685759156570237" LOG_EFFECT_SIZE="-0.3381156259409577" MODIFIED="2012-05-24 10:07:51 +0100" MODIFIED_BY="[Empty name]" ORDER="114" SE="0.62319" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="24" WEIGHT="5.043912938470836"/>
<IV_DATA CI_END="1.5045792135836282" CI_START="0.48862826796650854" EFFECT_SIZE="0.8574263438638795" ESTIMABLE="YES" ESTIMATE="-0.15382" LOG_CI_END="0.17741505755741616" LOG_CI_START="-0.31102141197013256" LOG_EFFECT_SIZE="-0.06680317720635821" MODIFIED="2011-12-19 16:24:43 +0000" MODIFIED_BY="[Empty name]" ORDER="115" SE="0.28691" STUDY_ID="STD-Heller-1995" TOTAL_1="33" TOTAL_2="35" WEIGHT="23.7967233899516"/>
<IV_DATA CI_END="Infinity" CI_START="0.0" EFFECT_SIZE="4.573943929259465E-9" ESTIMABLE="YES" ESTIMATE="-19.20289" LOG_CI_END="Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-8.339709163595135" MODIFIED="2012-05-17 11:05:41 +0100" MODIFIED_BY="[Empty name]" ORDER="116" SE="14786.0" STUDY_ID="STD-Pal-1998" TOTAL_1="21" TOTAL_2="13" WEIGHT="8.95998184464041E-9"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.3019244862256634" CI_END="1.333518177338031" CI_START="0.695893931222753" DF="3" EFFECT_SIZE="0.9633209261636346" ESTIMABLE="YES" I2="9.143894340563334" ID="CMP-001.04.02" LOG_CI_END="0.12499893998374878" LOG_CI_START="-0.1574569508996721" LOG_EFFECT_SIZE="-0.016229005457961618" MODIFIED="2012-05-24 10:07:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3473749491340502" P_Z="0.8218031283187066" STUDIES="4" TAU2="0.0" TOTAL_1="211" TOTAL_2="257" WEIGHT="71.15936366261757" Z="0.2252264316599941">
<NAME>Partial Onset</NAME>
<IV_DATA CI_END="3.849429643871038" CI_START="0.5542136632362837" EFFECT_SIZE="1.4606185348338254" ESTIMABLE="YES" ESTIMATE="0.37886" LOG_CI_END="0.5853963864255872" LOG_CI_START="-0.2563227715978552" LOG_EFFECT_SIZE="0.16453680741386598" MODIFIED="2012-05-24 10:07:52 +0100" MODIFIED_BY="[Empty name]" ORDER="110" SE="0.49443" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="30" WEIGHT="8.013069419680969"/>
<IV_DATA CI_END="1.8354576309125268" CI_START="0.4478872104929826" EFFECT_SIZE="0.9066851704353999" ESTIMABLE="YES" ESTIMATE="-0.09796" LOG_CI_END="0.263744363847759" LOG_CI_START="-0.34883133874224415" LOG_EFFECT_SIZE="-0.04254348744724255" MODIFIED="2011-12-19 16:24:50 +0000" MODIFIED_BY="[Empty name]" ORDER="111" SE="0.35983" STUDY_ID="STD-Heller-1995" TOTAL_1="25" TOTAL_2="28" WEIGHT="15.129124463987294"/>
<IV_DATA CI_END="1.2725333867923312" CI_START="0.562924531856658" EFFECT_SIZE="0.8463688681845762" ESTIMABLE="YES" ESTIMATE="-0.1668" LOG_CI_END="0.10466918551525271" LOG_CI_START="-0.24954982467817755" LOG_EFFECT_SIZE="-0.07244031958146241" MODIFIED="2011-12-19 16:24:50 +0000" MODIFIED_BY="[Empty name]" ORDER="112" SE="0.20807" STUDY_ID="STD-Mattson-1985" TOTAL_1="155" TOTAL_2="165" WEIGHT="45.24698014880551"/>
<IV_DATA CI_END="17.318638893828204" CI_START="0.641129820658237" EFFECT_SIZE="3.3321908480825115" ESTIMABLE="YES" ESTIMATE="1.20363" LOG_CI_END="1.2385137569580156" LOG_CI_START="-0.19305402245159364" LOG_EFFECT_SIZE="0.522729867253211" MODIFIED="2012-05-17 11:05:56 +0100" MODIFIED_BY="[Empty name]" ORDER="113" SE="0.84091" STUDY_ID="STD-Pal-1998" TOTAL_1="26" TOTAL_2="34" WEIGHT="2.770189630143794"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.1508772977705557" CI_END="1.1592339643577174" CI_START="0.7262860165857378" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.9175703887246252" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.06417109702923986" LOG_CI_START="-0.13889231736705548" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.037360610168907814" MODIFIED="2012-11-20 12:34:17 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5416887721018614" P_Q="1.0" P_Z="0.470781732217432" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="270" TOTAL_2="329" WEIGHT="100.00000000000001" Z="0.7212077132574415">
<NAME>Time to 6-month remission</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.8512708039857317" CI_START="0.4364627154836073" EFFECT_SIZE="0.8988941440476367" ESTIMABLE="YES" ESTIMATE="-0.10659" LOG_CI_END="0.26746995201836044" LOG_CI_START="-0.36005284967049567" LOG_EFFECT_SIZE="-0.046291448826067595" MODIFIED="2012-05-24 10:10:13 +0100" MODIFIED_BY="[Empty name]" ORDER="90" SE="0.36861" STUDY_ID="STD-de-Silva-1996" TOTAL_1="10" TOTAL_2="54" WEIGHT="10.47139028428894"/>
<IV_DATA CI_END="1.3329923124761622" CI_START="0.6005398525241264" EFFECT_SIZE="0.8947150422063043" ESTIMABLE="YES" ESTIMATE="-0.11125" LOG_CI_END="0.12482764479359708" LOG_CI_START="-0.2214581670170706" LOG_EFFECT_SIZE="-0.04831526111173674" MODIFIED="2012-05-24 10:10:13 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SE="0.20341" STUDY_ID="STD-Heller-1995" TOTAL_1="58" TOTAL_2="63" WEIGHT="34.386975013580624"/>
<IV_DATA CI_END="1.180389709530253" CI_START="0.5784144381262878" EFFECT_SIZE="0.8262895682555802" ESTIMABLE="YES" ESTIMATE="-0.19081" LOG_CI_END="0.07202541472684787" LOG_CI_START="-0.23776087491076678" LOG_EFFECT_SIZE="-0.08286773009195951" MODIFIED="2012-05-24 10:10:13 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SE="0.18197" STUDY_ID="STD-Mattson-1985" TOTAL_1="155" TOTAL_2="165" WEIGHT="42.967390861111475"/>
<IV_DATA CI_END="2.8370457666493087" CI_START="0.7428186903820921" EFFECT_SIZE="1.4516923299847313" ESTIMABLE="YES" ESTIMATE="0.37273" LOG_CI_END="0.4528663418032297" LOG_CI_START="-0.12911717732363157" LOG_EFFECT_SIZE="0.16187458223979906" MODIFIED="2012-05-17 11:23:08 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SE="0.34186" STUDY_ID="STD-Pal-1998" TOTAL_1="47" TOTAL_2="47" WEIGHT="12.174243841018958"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.82545727838478" CI_END="1.1384599792173293" CI_START="0.7097092986084886" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.8988746482931673" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.05631776827521143" LOG_CI_START="-0.14891950460921263" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04630086816700063" MODIFIED="2012-11-20 12:34:45 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7002830111682213" P_Q="0.513530773921735" P_Z="0.3765218137354658" Q="0.426866041208785" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="270" TOTAL_2="329" WEIGHT="99.99999999999999" Z="0.8843231327806766">
<NAME>Time to 6-month remission - stratified by seizure type</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PB</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.257576866182977" CI_END="1.2356436870283147" CI_START="0.5092618119926703" DF="2" EFFECT_SIZE="0.793262972180943" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.0918932546795276" LOG_CI_START="-0.293058889036204" LOG_EFFECT_SIZE="-0.1005828171783382" MODIFIED="2012-11-20 12:34:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5332378099189815" P_Z="0.3057292864032265" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="72" WEIGHT="28.424902626910992" Z="1.0242244515396017">
<NAME>Generalised seizures</NAME>
<IV_DATA CI_END="1.63998308033236" CI_START="0.14205997876204543" EFFECT_SIZE="0.4826758348644864" ESTIMABLE="YES" ESTIMATE="-0.72841" LOG_CI_END="0.2148393674646511" LOG_CI_START="-0.8475282545909465" LOG_EFFECT_SIZE="-0.31634444356314767" MODIFIED="2012-05-24 11:30:51 +0100" MODIFIED_BY="[Empty name]" ORDER="121" SE="0.62404" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="24" WEIGHT="3.7321820365478806"/>
<IV_DATA CI_END="1.3303414672593474" CI_START="0.47056760082658033" EFFECT_SIZE="0.7912114714337398" ESTIMABLE="YES" ESTIMATE="-0.23419" LOG_CI_END="0.12396312842020013" LOG_CI_START="-0.3273779778540452" LOG_EFFECT_SIZE="-0.10170742471692257" MODIFIED="2012-05-17 11:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="122" SE="0.26512" STUDY_ID="STD-Heller-1995" TOTAL_1="33" TOTAL_2="35" WEIGHT="20.67772201185436"/>
<IV_DATA CI_END="4.14864564733203" CI_START="0.3923182403451644" EFFECT_SIZE="1.2757701047512156" ESTIMABLE="YES" ESTIMATE="0.24355" LOG_CI_END="0.6179063415581872" LOG_CI_START="-0.4063614994231133" LOG_EFFECT_SIZE="0.10577242106753698" MODIFIED="2012-05-17 11:23:55 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SE="0.60166" STUDY_ID="STD-Pal-1998" TOTAL_1="21" TOTAL_2="13" WEIGHT="4.014998578508754"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.1410143709930183" CI_END="1.2489699771121647" CI_START="0.7144316347446618" DF="3" EFFECT_SIZE="0.9446182628423223" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.09655199887755408" LOG_CI_START="-0.1460393233092295" LOG_EFFECT_SIZE="-0.024743662215837688" MODIFIED="2012-05-24 11:30:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5436600067751929" P_Z="0.6892875477681353" STUDIES="4" TAU2="0.0" TOTAL_1="211" TOTAL_2="257" WEIGHT="71.575097373089" Z="0.3998221070028741">
<NAME>Partial onset</NAME>
<IV_DATA CI_END="3.8493479286915155" CI_START="0.5525099897357082" EFFECT_SIZE="1.4583563297666724" ESTIMABLE="YES" ESTIMATE="0.37731" LOG_CI_END="0.5853871671823447" LOG_CI_START="-0.25765986524851286" LOG_EFFECT_SIZE="0.16386365096691596" MODIFIED="2012-05-24 11:30:58 +0100" MODIFIED_BY="[Empty name]" ORDER="117" SE="0.49521" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="30" WEIGHT="5.926644295266297"/>
<IV_DATA CI_END="1.8115685990800854" CI_START="0.5069651074801791" EFFECT_SIZE="0.958332963818084" ESTIMABLE="YES" ESTIMATE="-0.04256" LOG_CI_END="0.25805478420983996" LOG_CI_START="-0.2950219305094448" LOG_EFFECT_SIZE="-0.018483573149802413" MODIFIED="2011-12-19 16:28:41 +0000" MODIFIED_BY="[Empty name]" ORDER="118" SE="0.32488" STUDY_ID="STD-Heller-1995" TOTAL_1="25" TOTAL_2="28" WEIGHT="13.770246722977165"/>
<IV_DATA CI_END="1.180389709530253" CI_START="0.5784144381262878" EFFECT_SIZE="0.8262895682555802" ESTIMABLE="YES" ESTIMATE="-0.19081" LOG_CI_END="0.07202541472684787" LOG_CI_START="-0.23776087491076678" LOG_EFFECT_SIZE="-0.08286773009195951" MODIFIED="2011-12-19 16:28:41 +0000" MODIFIED_BY="[Empty name]" ORDER="119" SE="0.18197" STUDY_ID="STD-Mattson-1985" TOTAL_1="155" TOTAL_2="165" WEIGHT="43.89227428129842"/>
<IV_DATA CI_END="3.214269884898314" CI_START="0.6036985859763504" EFFECT_SIZE="1.3930004251469124" ESTIMABLE="YES" ESTIMATE="0.33146" LOG_CI_END="0.5070823393225415" LOG_CI_START="-0.21917984137923782" LOG_EFFECT_SIZE="0.14395124897165182" MODIFIED="2012-05-17 11:24:06 +0100" MODIFIED_BY="[Empty name]" ORDER="120" SE="0.42661" STUDY_ID="STD-Pal-1998" TOTAL_1="26" TOTAL_2="34" WEIGHT="7.985932073547111"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.799347211342433" CI_END="1.0548319473472583" CI_START="0.6794237214704106" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.8465682767459187" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.023183274654309628" LOG_CI_START="-0.16785929419861445" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07233800977215242" MODIFIED="2012-05-29 15:51:48 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4236074858591985" P_Q="1.0" P_Z="0.13773587037166182" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="266" TOTAL_2="326" WEIGHT="100.0" Z="1.484275412731451">
<NAME>Time to first seizure</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PHT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.264147190873064" CI_START="0.5026515100968517" EFFECT_SIZE="1.0668069200065635" ESTIMABLE="YES" ESTIMATE="0.06467" LOG_CI_END="0.3549046566620273" LOG_CI_START="-0.2987330083726607" LOG_EFFECT_SIZE="0.028085824144683306" MODIFIED="2012-05-17 11:23:20 +0100" MODIFIED_BY="[Empty name]" ORDER="101" SE="0.38395" STUDY_ID="STD-de-Silva-1996" TOTAL_1="10" TOTAL_2="54" WEIGHT="8.542523036632472"/>
<IV_DATA CI_END="1.436766631697967" CI_START="0.6278743612359379" EFFECT_SIZE="0.94979415197319" ESTIMABLE="YES" ESTIMATE="-0.05151" LOG_CI_END="0.1573862331332768" LOG_CI_START="-0.20212725065894976" LOG_EFFECT_SIZE="-0.0223705087628365" MODIFIED="2012-05-17 11:23:20 +0100" MODIFIED_BY="[Empty name]" ORDER="103" SE="0.21118" STUDY_ID="STD-Heller-1995" TOTAL_1="58" TOTAL_2="63" WEIGHT="28.23773975756668"/>
<IV_DATA CI_END="1.1877355408708856" CI_START="0.6309121891943604" EFFECT_SIZE="0.8656539899259971" ESTIMABLE="YES" ESTIMATE="-0.14427" LOG_CI_END="0.07471975215526344" LOG_CI_START="-0.20003108196362776" LOG_EFFECT_SIZE="-0.06265566490418216" MODIFIED="2012-05-17 11:23:20 +0100" MODIFIED_BY="[Empty name]" ORDER="104" SE="0.16139" STUDY_ID="STD-Mattson-1985" TOTAL_1="151" TOTAL_2="162" WEIGHT="48.348417011644194"/>
<IV_DATA CI_END="0.9802080043535721" CI_START="0.31327010055190585" EFFECT_SIZE="0.5541388454941835" ESTIMABLE="YES" ESTIMATE="-0.59034" LOG_CI_END="-0.008681755371242604" LOG_CI_START="-0.5040810535222888" LOG_EFFECT_SIZE="-0.25638140444676566" MODIFIED="2012-05-17 11:23:20 +0100" MODIFIED_BY="[Empty name]" ORDER="102" SE="0.291" STUDY_ID="STD-Pal-1998" TOTAL_1="47" TOTAL_2="47" WEIGHT="14.871320194156649"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.470088162299925" CI_END="1.077121220642088" CI_START="0.6900965307071634" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.862158696248069" ESTIMABLE="YES" I2="7.265560383536144" I2_Q="50.99833155316799" ID="CMP-001.08" LOG_CI_END="0.03226458212197965" LOG_CI_START="-0.16109015589862724" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06441278688832376" MODIFIED="2012-11-20 12:34:59 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.37263815221252994" P_Q="0.1531348719813408" P_Z="0.19160146141641266" Q="2.0407468392326766" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="266" TOTAL_2="326" WEIGHT="100.00000000000001" Z="1.305856207480301">
<NAME>Time to first seizure - stratified by epilepsy type</NAME>
<GROUP_LABEL_1>Phenobarbitione</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PHT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.404681148729958" CI_END="1.7755231955237811" CI_START="0.7318520322142928" DF="2" EFFECT_SIZE="1.1399211634528479" ESTIMABLE="YES" I2="16.82889013970489" ID="CMP-001.08.01" LOG_CI_END="0.24932635031951608" LOG_CI_START="-0.13557671687696873" LOG_EFFECT_SIZE="0.056874816721273654" MODIFIED="2012-11-20 12:34:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3004901322814272" P_Z="0.56243788283731" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="72" WEIGHT="25.235208273882247" Z="0.5792242354052658">
<NAME>Generalised seizures</NAME>
<IV_DATA CI_END="6.195118791797853" CI_START="0.8084780977375898" EFFECT_SIZE="2.2379941590743986" ESTIMABLE="YES" ESTIMATE="0.80558" LOG_CI_END="0.7920496384163072" LOG_CI_START="-0.09233174095306393" LOG_EFFECT_SIZE="0.3498589487316216" MODIFIED="2012-05-24 11:29:02 +0100" MODIFIED_BY="[Empty name]" ORDER="124" SE="0.51949" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="24" WEIGHT="4.780028184485954"/>
<IV_DATA CI_END="1.829237821762838" CI_START="0.6020351845668126" EFFECT_SIZE="1.0494119923278866" ESTIMABLE="YES" ESTIMATE="0.04823" LOG_CI_END="0.26227017237903766" LOG_CI_START="-0.22037812665464995" LOG_EFFECT_SIZE="0.02094602286219383" MODIFIED="2011-12-19 16:30:29 +0000" MODIFIED_BY="[Empty name]" ORDER="125" SE="0.28351" STUDY_ID="STD-Heller-1995" TOTAL_1="33" TOTAL_2="35" WEIGHT="16.0490037042061"/>
<IV_DATA CI_END="2.140259990955324" CI_START="0.25664350099102884" EFFECT_SIZE="0.7411368410150733" ESTIMABLE="YES" ESTIMATE="-0.29957" LOG_CI_END="0.33046653305893714" LOG_CI_START="-0.5906697289464514" LOG_EFFECT_SIZE="-0.13010159794375714" MODIFIED="2011-12-19 16:30:29 +0000" MODIFIED_BY="[Empty name]" ORDER="126" SE="0.54108" STUDY_ID="STD-Pal-1998" TOTAL_1="21" TOTAL_2="13" WEIGHT="4.406176385190192"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.0246601743372903" CI_END="1.0149814962119466" CI_START="0.606513377744163" DF="3" EFFECT_SIZE="0.7846017178258865" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.00645812484401287" LOG_CI_START="-0.21715961554531232" LOG_EFFECT_SIZE="-0.10535074535064975" MODIFIED="2012-05-24 11:29:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5673042399832562" P_Z="0.06478255720039953" STUDIES="4" TAU2="0.0" TOTAL_1="207" TOTAL_2="254" WEIGHT="74.76479172611776" Z="1.8467556846986275">
<NAME>Partial onset</NAME>
<IV_DATA CI_END="1.786346970261501" CI_START="0.16181642976486452" EFFECT_SIZE="0.5376432730435662" ESTIMABLE="YES" ESTIMATE="-0.62056" LOG_CI_END="0.25196581772983523" LOG_CI_START="-0.7909773851095991" LOG_EFFECT_SIZE="-0.269505783689882" MODIFIED="2012-05-24 11:29:09 +0100" MODIFIED_BY="[Empty name]" ORDER="127" SE="0.61263" STUDY_ID="STD-de-Silva-1996" TOTAL_1="5" TOTAL_2="30" WEIGHT="3.437069557038827"/>
<IV_DATA CI_END="1.5681196605506385" CI_START="0.42630627606372207" EFFECT_SIZE="0.817618036072866" ESTIMABLE="YES" ESTIMATE="-0.20136" LOG_CI_END="0.19537919988796146" LOG_CI_START="-0.37027827364003896" LOG_EFFECT_SIZE="-0.08744953687603883" MODIFIED="2012-05-17 11:09:26 +0100" MODIFIED_BY="[Empty name]" ORDER="128" SE="0.33227" STUDY_ID="STD-Heller-1995" TOTAL_1="25" TOTAL_2="28" WEIGHT="11.684296749481073"/>
<IV_DATA CI_END="1.1877355408708856" CI_START="0.6309121891943604" EFFECT_SIZE="0.8656539899259971" ESTIMABLE="YES" ESTIMATE="-0.14427" LOG_CI_END="0.07471975215526344" LOG_CI_START="-0.20003108196362776" LOG_EFFECT_SIZE="-0.06265566490418216" MODIFIED="2012-05-17 11:09:26 +0100" MODIFIED_BY="[Empty name]" ORDER="129" SE="0.16139" STUDY_ID="STD-Mattson-1985" TOTAL_1="151" TOTAL_2="162" WEIGHT="49.52581124068465"/>
<IV_DATA CI_END="1.0584910328143835" CI_START="0.26110194867942843" EFFECT_SIZE="0.5257129172157903" ESTIMABLE="YES" ESTIMATE="-0.643" LOG_CI_END="0.02468718317193771" LOG_CI_START="-0.5831898868995196" LOG_EFFECT_SIZE="-0.2792513518637909" MODIFIED="2012-05-17 11:09:26 +0100" MODIFIED_BY="[Empty name]" ORDER="130" SE="0.35707" STUDY_ID="STD-Pal-1998" TOTAL_1="26" TOTAL_2="34" WEIGHT="10.117614178913213"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-11-20 12:26:43 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-11-20 12:26:43 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-11-20 12:26:43 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="withtime.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-06-19 09:49:04 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to treatment withdrawal</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="withtimeeptype.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-06-19 10:11:41 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to treatment withdrawal - stratified by epilepsy type</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="remtime.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2012-06-19 09:50:42 +0100" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to 12 month remission</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="remtimeeptype.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2012-06-19 10:18:53 +0100" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to 12 month remission - stratified by epilepsy type</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="remtime6.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2012-06-19 09:52:14 +0100" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to 6 month remission</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="remtimeeptype6.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2012-06-19 10:19:28 +0100" MODIFIED_BY="[Empty name]" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to 6 month remission - stratified by epilepsy type</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="seztime.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2012-06-19 10:19:48 +0100" MODIFIED_BY="[Empty name]" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to first seizure</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="seztimeeptype.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2012-06-19 10:20:25 +0100" MODIFIED_BY="[Empty name]" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to first seizure - stratified by epilepsy type</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="mattison.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2012-06-19 10:22:01 +0100" MODIFIED_BY="[Empty name]" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Time to 6 month remission - Mattson 1985</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmAAAAG6CAIAAAAgRG1TAAAc40lEQVR42u3dwXXjuAGAYVeyHeQYH5IytgGd0oqv24fuKcMNpIE5TgcbW5IpEARAUKIkAvy+N2/fzliWTdHSb1Ag+PYbAJh48xAAgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACAAIJAAIJAAIJAAIJAAIJAAIJAAJJc46Ht7e394/P6Uc+P97f3nIfvM35Lg/HB2/Tz3ee/9ZPW734W8k/Vv3t/Y3v4u8v9HF8+q4Zf1EEkn0G8gF1fEEgc9/+Tx8Fss1ATr/IE3bN09KPQLLll8jH1PEVgUxvwtBHL3dtZuQlrRJIgUQgH1bHZwfy/XB4T27G9yafP+jlTiAFUiChLpBzdQzGZokx2PUl5DpGy9yg7g6H7250s9nXqEsgP44fqUKe+nj+2OSuxt9O/NHkcbzip5w++PVvw+OR/7UjeMimt0t85fFjmfhCH4fkgzX6vPB+jxW3X/IzUDnGT986/2hEXz785n9ulvo5vHyN4LPL+358i/QXvXtbEEjaCeTlmZx5Ck9fQOKn/OWF6SO+YXyDY+0dRq8ttS8yP4E8dzXRmiG5k7exJopvdM1+yrlbh8PMN55+JIIbVwZy/IWSxRv/4+h+K25f/TNwnPmJm33Qsl+hPpCHQ/QV4ju+PqBz25UL5J3bgkDSSCDnJq6cPz5+akdFvb4aDPdxucXo9/dw9FK+w+Gbmgxxi0OUIZC/p4W89HHyQj7+RsOvFd1mUu/Sp9Qdr54+EtctWBLI9NgmOSQvHD8o3L76ZyC/e+YftPlHY26SzvBzOL7L/JbU/Cj+zv5Kdd+2IJBsPZDv77f9gjt+ul9eHVIvNOdXjPnhRfT6kXjlyhwJzNxJXMifPsbfSmYW5OmfMzeq+ZS6l8PU6/Pswd1UINOHf4PHKr6f6O+zt6/9GcjunooHbf7RqAxkvB2Jwf+CH8XqB2fhtiCQbDyQ11+Ek42bOyg4fmGKPzd4HSm8eibvcC4MkyNcYYeDLzm6v9S3kj3Elv9uqj6lcmJHtB2ZF935QM69gZg+RpwfmpX7WPgZyG1x1YM2+2jUBXI6bpuO/hb8KE7uY6VtQSDZfCCnz/vpa8fsG1Czw5joNWb+Ha37Azkq5LWP0beSea/zLXGkLvPSl/6U+pmPqbvLHtytDmR+Sk7mfmduX/szkNviusd57tGoC2R56lAUyIr3wzMH5e/dFgSSrR9iTb4Ijp/F4fM8el25bQRZcYfzYag96Hf6S9DHyr4UHquqT1l+akB6TuTNgQw/dXy8OHe/pdtX/wyUR5D1j0dmhujagaz5UcyMIO/eFgSSpgL5OzWftXSKw03vQdbc4SqBHAoZ9jF5MHHuVSs1Y6X8KXecOzczwTR6n63whS53lDyvJbUT8rev/xkovwd5wwMyN5vorkBW/Shm3oO8e1sQSFoLZG4+afoch8nbcrlJp9PDo+U7XCeQl0K+v9ccMCvNSU3PYr2xW/kvk3i841fryTzN0hc6jwQPh9ozO7O3r/8ZmJ3Fmn/QKh6NhwRy7kcxP4v1vm1BIGkvkJOnf+ktl1H/oimx2UNjFXe4UiBTJ0HUngdZnLY4+ym3TdJJTOmYvEcWLQVU/EL5M3iKxw8yPb33XdfZB23Ro1FeKOCGQ6xv5R/emvMgF20LAkmLgZy+GZmYkjedDzM+qbJ8Yt7cHa4VyKp5jYlvqOKAZPlTFhxinZ3vGL1AL3kTNXu2SXGp+pl1bEs/A1Xv5pbekJt7NOJTbu+dpDP/o/g7eZ7vGtuCQLIHToIGBBIEEhBIEEhAIEEgAYEEAIEEAIEEAHYfyL8B2AeBXLj9b29+aIAteGNVuw5k7jIzi5YAFkhgO4H0IDz0wdxLII+H4hUIqiPpJxIQSIHsKZDfFSxeF6e2kH4iAYEUSIEUSEAgBXIPh1jT6644xAoIpAdz35N0Kq7CJ5CAQHowdxhIp3kAAolACiQgkAik8yABr+k9+d9f/5q+Wv/rr/9lP/qf/wpkC+dB3r+aw/Df5IemHw0/JdzT4f9Enw4I5MYDOfQwqOK5g5OP/vc/dzbSaR5POs1DIAGBXD2Q5wyeKjj9aPL2AimQAgkCKZAC2cR5kAIJCOTqgQwOo6YOsd6TR5N0bjsPcnr7X3l//OPPrz93BvKvf/57+G9kuPPoo+d/j/57/p+vWw43Hj79F9C+5Gv6+SnfxJ/ZQL5lJ+KUP3pjIKePsNM8dneax1cm/eoNRpANHmItfPQ0vLxjEOk8SIEUSBDILgMZvEEpkE+bwSOQgEAKpBGkQAIC2WIgzWIVSIEEBDI1See+SawCKZACCQKJQApkztzsakAgPZgCKZCAQGKpuaIdzWIVSBBIBHLkdLmrRde2EkhAIAVyH4dY8yuymqQDCKQHc8eB9B6kQIJAIpACKZAgkAikQAokeE1HIAVSIAGBFEiBFEhAIAVSIAUSEMj0JZGH9VZTV+64/FvyE+cvqCyQAimQIJDNBDJaf/yUvnPlCoEs34dACqRAgkB2F8iggQIpkI9hJR0QSIEUSIEUSBDITgL5XUCHWAVSIIHbXtP/+MefuT+Pu1nhloWbzQYyP83m1MrZeTgCKZACCQK5hxFkcbRoBCmQazBJBwRSIAVSIAUSBFIgBVIgBRIEUiAFUiAFEgRSIAVSIAUS2FUgN/FgCqRAAgLpwRRIgRRIEEgEUiAFEgQSgRRIgQSv6QikQN7BSjogkAikQAokCCQCKZACCTt7TWdFAimQAglQRSAFEgCBFEizWAEEUiAFEkAgBVIgAQRSIAUSQCAnPj8/BVIgAQQydjz8nLby/vEpkAIJIJDJSj41lQIJIJCtvAf51FQKJIBANjZJ5zmdtFAAgEC2OII8HM/TeD7eg78JpEAC7CqQiTIGU12/Gzn86/dNg5uMRpuLMiqQAAK53UAWyzgbyK//Hx1/jf8ukAC0fJrHooHfNZDf4Yx6GA0vBRKA3aykEzRwOmDcWSDNYgXoeQSZDNr4sGruoOz7l+gQa/1wVCABBHJrgYzO48gptu4yvTUcTi47WCuQAAK5uRHkULeCR6+oI5AAAtneIVZLzQkkwJ4Deevh2TVGlwIJIJCbfA/ye+RYfjMyO0nn8HE+RHtXJwUSQCC7C+QxfivzhuO0AgkgkJ2eB5meF+s8SAAE0mLlAHQUyHvOg7w9kNMv8KtxX4H8BcCcnS0UYARpBAngEKtACiSAQD7pDUqTdAAEsqfTPIwgBRJAIAVSIAH2FEjvQQokgEA+8WIgi4acAgkgkBsP5KR3xdDlL/y47JKQAgkgkBsOZPbKkLmFyIsTVc1iBaCLQH4mr8rxWbpWh0AKJED/gfwOWrKDhaOl2c9xiBWArkaQqaR9f6BwtcfM6SF7m6RjJR2AXgN5SWTqEOtdF0MWSABaDKTFygUSQCAFUiABBNJKOs9kkg6AQAqkQALsK5DZlQIcYhVIgP0GsvhupEAKJMBOAxmc0BGe+bjsjH+BBKC3QIar4oxWyJlZKEAgBRJgN4Ecr6qzZFVVgQSgs0CeZ+hcQhgeWH3CQVaBBBDIDc9ivczSObUwmrHz4DchBRJAIDd9HuTo0OrQyIcvxWolHQCBtFCAQAIIpEAKJAB9BHKymM6jT4EUSACB3HogsyvNuR7kPJN0AHoN5CWPqQsmv1koQCABdhvI0eo5k7M/nAcpkAB7HkGmOmipOYEE2HMgR8uVF/9NIAUSoP9AFi9y5XJXAgkgkAIpkAACaaEAgQQQSIEUSACBXHmxgMevVG4lHQCBtJKOQAIIZGuBPE/XSa+k43qQAgmw10BmV9LJriAgkIEONgFAIAVSIAEE0iFWgQQQSJN0BBJAIJ8SSRdMrg6kUyEBOg6khQJu9Nc//y2QAF0G8glzcQQSQCA7msV62xuXi1LbTSA1EqC/QN6SyNPE12QK8x+xUACAQDY3glx4uavvT8lGsPhBgQQQSIEUSAAaDuS6B2UdYgVgx4EsjDx3OEnn/D/nqTom7AB0EchwKupTLgC5hxGkQAI0HsjEEPDZp0MKJIBAbi2Q58Hjddh4zmVdIaN5OKPS7vYQaxhIB1oB2g3kdDZN/fyaMJBf/z86OBv/3SQdAJoL5Lhk9WvOXQP5/TlRD53mAYBAJgaMAgnAngM5TH79Eh1i3dt5kMNj8ff48pDR25CuHAkIZPeBnJwlch1OztzD9LzJX40LA/n113CLhtk65792sLEAN2ttks68x5740fcIMhpHGkECRpACKZACCdBqIB9a3n1N0hkCef7/aNrOcKBVIAGB3HcgdzaCTCbTMwFAIAVycSANJQGBFEiBHDm/HymQgED2HMjwQiB7vtxVMpDJPwIJCGT/gcyf8Li7CyYvGlZGgVRKQCA7C2RxourOZrEuDWQ4nVUgAYHs7DxIgbwxkGfOjAQEstuFAqbr1DnEOhvIoZHD1SKHzXf9SEAgO5rFmimsSTo1g8gpgQQE0mkeAimQgEC2EcjcKRvWYn1IIIeFW4e//u0oKyCQGwxk8d1IgXxSIA0iAYHcWiBPw8fzjJvv//2Ze7Nsto1ACiRAb4EMZ6SOZqeGuRTI5wTSUjuAQG4zkKfR5DBsXHJGo0DWBPL8Z7g21vDXcP5OlE8AgXztDJ1LCMMDq084yKoE0eBSIAGB3NIs1sssnVMLoxk7D34TUgkEEhDITZ8HOTq0OjTywW9ACmQukGbrAAJpoQCBvAQyfEvyK5CzV10GEMiXXppDIF/hPJ01vO4HgEC+dp2Axx9UFcjqMaVAAgK5vbXHnxVKARBIQCBbeQ9yPI3VLNbXBfJvKwYAArlJ51I6D/JlgRzWEMj98SgBAvmyEaS1WDc+xAQQyOesp/OsMApktdw5kQIJCOQzh4zPPt1DIGsCmWykQAIC6TxIjUwH0luSgEBaSWfvgZx9oKaBjK6o5aEGBHLJkdXvkWO0PHnELFaBBBBIgdwqgQQE0iFWBBIQSJN0vGqvF8joT7jIgEACAmmxcmqHmAACabFyLO4KCKTFyjuVW1JHIAGBtFi5QAokIJAWK6cikPUPoEACAmmx8m4DGf65IZCF62d5eAGBtFh5V6PJVR5AgQQE0nmQvXlaIKdfyL4Dug/k6eDqiwrpRfb+QEYHXQUSEMg1R5DPXiBAINcmkIBAdpVIL7ICCQhkE5N0Kq/mEb1tefuZIV5kNxLI2T/T6a/Dv3jwAYFMBvLr/0ejz/jvArn5QN5DIIGOA3nXxNfvGT5RD5fMihVIgQQEss9AJgaMArknAgl0HMgbD7EOF/74Eh1irX8fUiAFEhDIngI5WZ/uOpxcNktHIAUSEMjWDrE+ZYEdgRRIQCDbew/yCYkUyBW9ZJ5OzSkiuT92GQhkq4Esr0EXHJkd38YknT0F0tAT2GEgSxdMHq29E73zKJACKZBAF4EsTtLJ93E6bLz8k0AKpEACnQeyeHh18sGfI7ICKZALA+nHAASym4UCcsubD60VSIEUSGCXgfyJ4TSS51Mjs4GcDlN/sZKvQDb03X4Fcvh/PwawB80F8tSzIHPDqf/PuYayoYMRpBEkGEFuMJDxEdGgjpdl5B59kUivjLtVvpaWcyhBIN9ePXgMGzg+aFo6y2O19QUEkjtHn4BAPvzg6vRNxcxMHCPITfvjH3+2daxVIEEgtxbIOH+TYM6spCOQW26kQAICuVogp1fiEEiB7COQj/4x29SPsecUArn6SqvTPmbO40jMd62/PpZACqRACiQCuflJOmEAJ2cvXvKX62P+wo/LLgnpyfygQPbdSIEUSATyKdNYJ+d0XJeeyw4fixNVzWI1iBRIgYS2Azlq5DVpk9M/BLLtQPb3IC89afKG8yw3df/tfjPOXqXlQK68FqtDrAIJ64z7EciG12LNXQXEJJ2t8SAjkAhke7x2CyQCiUAKpEA+23k669eD3P2JHwgkAimQ3FhKDwICiUAKJAKJQCKQAolAIpAIpEAikAgkAimQCCQCiUAKJCCQCKRACiQIJAIpkAIJCCQCKZBbdV40IPmn8h6SO8se5CWB9IO3TeX9IpACua8ffXsQgUQgBXIXo0yBRCARSIFEIBFIBFIgqQtk4e3J86Ln0R8roVMfyJ1cF3rPfwRSIAFYTCAF0kFaAIEUSAQSEEiBRCABgRRIBBIQSIFkvUDmJsEuWrUHEEiBFEjjS0AgBVIgBRIQSIEUSAQSEEiBRCABgRRIbg1kbvLO7HW4ll6cCxBIgcQYFBBIgUQgN+C1P7e5r+7ZhEAKJAIpkAKJQAokCKRAIpACCQIpkAikQAokKwRy6STYVW6WvHZ0cpLtI7695FcXSARSIAEQSIEEQCAFEgCB7CGQnx/vbymHo0ACsNdAHg+5FOY/IpAAAtl7IL8rmI1g8YMCCSCQAimQAOwrkKcIvn98OsQKgEAmU2iSDgAC6TQPAARSIAEQSOdBAiCQzoMEQCCd5gGAQAokAALpPEgABLKX8yCnt/8FwA44zcNpHgDsfAQpkAAI5FozeAQSQCCNIAUSAIEUSAAEUiABEEhrsQIgkNZiBUAgLTUHgEBuNJAA7IG1WJcdYp3N528an4TlQbATsQdv/M4bXxDg3kk6npmemdiJ2IPdBdJ+xR60E7EHBdJ+xR60E7EHBdJ+xR7ETrQHBRIABBIABBIABBIABBIABBIABJKT6yo96QXt2IbommfBzsrtQXt2Y8+zeDcs3XF26Lb2YF9PSYHMvOpedtVpb6+4eB0Pf4Et7UF7dnu/ho7239IdZ4dubQ929pQUyPROv+6mJdcG4QW/yiR2Tm4P2rMbe2mNRw1Ld5wdurU92NtTUiBLv+p42jU5gMztQXt2U3vu66GP9sjSHWeHbm0PdveUFMiZ33U86za+q97f3+PruOT2oD278V9Gl+44O3STw4menpICWRVIb/9v9ckZ7Jrh4E5uD9qzDQaytOPs0K3twe6ekgJpBNndnjPgMILkNSPI3p6SAll10MCzrqVAesuq4fGH9yB7DKT3ILsdQnrStTTWPz/ZTHrs4pdRs1h7OAbQ9lNSIDMvvE6uauTZOXp2/TxVc3vQnt34+GPpjrNDN7YHe3tKCmS+keN5WGx8R2WX5xjvQXt2y4G8YcfZoRvbg109JQUSAAQSAAQSAAQSAAQS2hNMXkg4z0+IViJ59PeT+0oPn09Y+NogkCCQrwxkMVGPn3A/c4I5CCTs1DNHirlYFwL4jDPSnNaPQAL1gQz+ffjfn5Hn5ebpy/BFI9RyeVL9G52MNrnBePQ7fOXUZoSfO7q6fPw9GUQikMDtgTwc3sMwHcPiBM1JHL5dcAD1c3yvl68aXvM9c0Q4sR2n7+T00cTnjRtp7RsEErg1kNeoROPI80dHfwlac/6HTHsyw8PxsDBqYHj70T/EGxL1MfmR34V/AoEEgawK5Hgh5+hSe/HB2LrRWXzNvemnZ/saDFRH48vhs4PkDQPIfAFf/U4sCCQ0G8jCCOzauez02GR7Jl86MY4b57V0jHUc3PFdxd/X9NsxhEQggWYDOV1KOvud5O4p+y6kQCKQwAMDuWyyy+RLJ76X+Ejp6M6nB2Av30p87DY1XBzflUAikMADAzmesZOJ2O/UJ4blmsxaDd9KjN4KfUvcw2nqa/z9VrzX6T1IBBJ4VCDTR1mL68jlrtQ3Pc0j+Q5k5g4SU31mP8sAEoEEHhfISY9K2Ukekr1++nShgLCfw9IFifcaJxtU/p6cB4lAAhvM86pluuVgqZV0EEhgc2bm09xyd0vvz1qsCCSw0USuUcjpSSCGjwgkIJE/7zIuvSPXg0QgAUAgAUAgAUAgAUAgAQCBBIDVA5laSXGts3+dJgVA24FMXL9GIAHYfSAPHx/v8cVXBRIAgTyOF8UYAhkVbvjr+X+O11X+v/81WPQ/uMbO+8fHIXWVnPASAeE17L5jfcOiVwDwkECe43RcEMhr8KKFqq5XGRjdLLz4wOhCBNcvUrpALAC8JJCnPF1aVhfIa8gSf83d7PTv8SHcMNL6CMDGAnldfLjyEOv03xM3S4QweXXzn4O03rMEYHOB/CnaEwKZ7KBAArDNQF6Os36sGMjUv+cu9CqQAGw1kNGJkWHKgik3CwKZn6QzfMbwRQQSgO0GMlpcZ3Tyxs+blItGkMNpHqMvE74RGSZYIAHYRCABQCABQCABQCABAIEEgFcFcrze6vCvx+Nn7rapxXGuHy9OTzV/FYBGAnlaBecwWUWgfgmcRQurCiQAbQTyfHpkbrXxur4tuKykQALQRCB/FrcJCvk5vvrjokCGHx8fjh1dOfJz+DQX9QBgi4G8rjCXuXJjxQAwXI+ntDrrcKGr1BWyAGBDgQyPjcZLqGYDOZW5QmQqf+cbHEdLtALAtgI5fu8wOspaMYL8nHQu+Pjx8JZYmnW04qsdCsAWA3lNWDwarD/EOlrvPPmJx0N8zz9XojSEBGCDgUy8CTh9p3A2kIlLgiQ/8Wewer2BRAKwxUAmJ8kM/5g7cSN7HmR8bPaYObEyuINPb0QCsLlAZiaRDtEaXU25HMhwLZ7pWRylK0FKJACbG0ECgEACgEACgEACAAIJAAIJAB0EMrlM6/iMjtwKrsscD7lTQ+KTUK5ftMFzScKzZEYP1fUD/Zwh0+M2FZ4cvW9k16du5V9/bKBAlp8e0eNaWt01WqNu2UtpYSH164eCtQqaW7Vn9OiE3334w9vLWkTh6bCdXi+0+xfVtp9uq7z+2ECBXBjI4Fkz/egNL4XDOCPxeae7e39Pr0jQ2utu9ApTuohY+8/VaGMXXH27qV8B+l6bv+mn2xqvPzZQIF8dyK87+7qv5OedX4Hyd9n2MzZcwK+/52ZuVUIDyE5y2dFezL3+2ECBvOFJERwoTB1ivW0vZA7lFtdYb3tUMgyxLtuZvpBYTyPIzoZbpy1838913no8CNB5/DvZwOYm6QxPk/JH79p/1+NXubdBWz4oEr5BFy+Q28nAJEziZX919fIaLTnc8/HW5p9uAimQL3lcpx+99c3gxPtwsxfbavWX2vBCKb8Tkx+6+VU9ePPj2PsLUN8DrO43USAF8imBvPVZNJ0OUDUybe8pO/0NYjL26HVCi0DaRj+fNlAg7w5k9kPxnTf2jE1fjiyxUe0/V7ufANnlXpvfRoG0gQJ5eyBv3Q+VgYyGW229KGW3cbKF3ZwHeX0Xub8X1pZ/FG2jQArkcwKZW2XnMYEcf9Gm9njxuHGrGzU7AOl6imewLlK3r65d/mQKpEACQOMEEgAEEgAEEgAEEgAEEgC6DmT5ksipU4Ov//bYCybnrrfb8nV4U5efDS+i3NN5Ef1fTzh7+es+N7Lfy13YQIEsvYzlL4k8H8gHXTA5dw3h4Eu2d/55zeVn+7kubeeXg8pe/ronTT/dbGAfG7i5QAav5AsDudYFk7PXEB5/P20tfVWz+lpHL7SdX084d/nr7jay1aebDexlA/cdyOT1PHODj/juG/6JTj1SXf0Ou6/rCXcZyI6ebjaw3Q3cXCCDg0fLD7GuccHk7DWE+1k9OffAdvMiu6/rCfd5iLX7xcptoEDWpCk/RyQ1geR6g0ddMDl7DeHU/m7tdSl7+dmunp07up5wvK19v7x2tZ02UCBvGEFWDHRyh1jXuWBy9hrCPf3Gt59rCXW9ddHlr40gbaANFMhcINe7YHLyGsJdvWfQ/QSB/gN56++DDcXfW3Q2UCA3Fsj81Whbjkrxt7neJnns4HrCfZ4WsK/f4WygQD41kGtdMDl7DeHg6GtzL1Cly892+btrz9fa7f4Kgs0/3WxgJxvYdiAfdsHk7JVaW74Ob26juny57fl6wuvNT2tnL3Z/2WsbKJAAIJAAIJAAIJAAIJAAIJAAgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACgEACwJ79H6q4u3N8E9kFAAAAAElFTkSuQmCC</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-06-21 17:23:14 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-06-21 17:01:14 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-09-10 16:08:57 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-06-21 17:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>#1        (phenytoin OR epanutin)<BR/>#2        MeSH descriptor Phenytoin explode all trees<BR/>#3        phenobarb*<BR/>#4        MeSH descriptor Phenobarbital explode all trees<BR/>#5        (#1 OR #2) AND (#3 OR #4)<BR/>#6        MeSH descriptor Epilepsy explode all trees<BR/>#7        MeSH descriptor Seizures explode all trees<BR/>#8        epilep* or seizure* or convulsion*<BR/>#9        #6 OR #7 OR #8#<BR/>10        #5 AND #9</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-06-21 17:23:14 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-10-17 16:07:02 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-06-21 17:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>The following search is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>1. randomized controlled trial.pt.</P>
<P>2. controlled clinical trial.pt.</P>
<P>3. randomized.ab.</P>
<P>4. placebo.ab.</P>
<P>5. clinical trials as topic.sh.</P>
<P>6. randomly.ab.</P>
<P>7. trial.ti.</P>
<P>8. 1 or 2 or 3 or 4 or 5 or 6 or 7</P>
<P>9. exp animals/ not humans.sh.</P>
<P>10. 8 not 9</P>
<P>11. phenobarbit$.tw.</P>
<P>12. exp Phenobarbital/</P>
<P>13. (phenytoin or Epanutin).tw. or exp Phenytoin/</P>
<P>14. (11 or 12) and 13</P>
<P>15. (epilep$ or seizure$ or convulsion$).tw.</P>
<P>16. exp Epilepsy/</P>
<P>17. exp Seizures/</P>
<P>18. 15 or 16 or 17</P>
<P>19. 10 and 14 and 18</P>
<P> </P>
<P>Earlier versions of this review used the following search, combined with phases 1 and 2 of the previous Cochrane Highly Sensitive Search Strategy for MEDLINE as set out in Appendix 5b of the Cochrane Handbook for Systematic Reviews of Interventions (version 4.2.4, updated March 2005) (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<P>1. phenytoin/ OR (phenytoin or diphenylhydantoin or epanutin).tw.<BR/>2. phenobarbital/ OR phenobarbit*.tw.<BR/>3. exp epilepsy/ OR epilep$.tw.<BR/>4. exp seizures/ OR seizure$.tw.<BR/>5. convulsion$.tw.<BR/>6. 1 AND 2<BR/>7. 3 OR 4 OR 5<BR/>8. 6 AND 7</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>